

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 October 2001 (18.10.2001)

PCT

(10) International Publication Number  
WO 01/77307 A2

- (51) International Patent Classification<sup>7</sup>: C12N 9/00
- (21) International Application Number: PCT/US01/11144
- (22) International Filing Date: 6 April 2001 (06.04.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/195,598 6 April 2000 (06.04.2000) US
- (71) Applicant (for all designated States except US): CYTO-CLONAL PHARMACEUTICS, INC. [US/US]; 9000 Harry Hines Boulevard, Dallas, TX 75235 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): BERENT, Susan, L. [US/US]; 14343 Valley Hi Circle, Farmers Branch, TX 75234 (US).
- (74) Agents: HANSEN, Eugenia, S. et al.; Sidley & Austin, Suite 3400, 717 N. Harwood, Dallas, TX 75201 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/77307 A2

(54) Title: EXPRESSION SYSTEM FOR EFFICIENTLY PRODUCING CLINICALLY EFFECTIVE LYSOSOMAL ENZYMES (GLUCOCEREBROSIDASE)

(57) Abstract: The invention as described herein relates to the efficient production of recombinant, clinically effective lysosomal enzymes using a transformed insect cell expression system. For example, to create the expression system of the invention, any insect cell can be transfected with a plasmid comprised of a gene encoding the human glucocerebrosidase gene and genetic elements that enhance its expression. The insect cell transfected with the plasmid encoding glucocerebrosidase secretes synthesized glucocerebrosidase into its growth media. The recombinantly produced clinically effective glucocerebrosidase produced by the insect cell expression system can be used to treat Gaucher's disease.

**EXPRESSION SYSTEM FOR EFFICIENTLY PRODUCING CLINICALLY  
EFFECTIVE LYSOSOMAL ENZYMES (GLUCOCEREBROSIDASE)**

**TECHNICAL FIELD OF THE INVENTION**

5           The present invention relates to a system for efficiently producing clinically effective glucocerebrosidase.

**BACKGROUND OF THE INVENTION**

More than thirty genetically inherited lysosomal storage diseases have been characterized in humans. Lysosomal storage diseases, although relatively rare, can be fatal if  
10   left untreated. Ubiquitous among animal cells, lysosomes are intracellular organelles that contain hydrolytic enzymes. Lysosomal storage diseases are caused by the accumulation of a deficient enzyme's substrate in lysosomes, thereby increasing the size and number of lysosomes. An increase in the number and size of lysosomes results in gross pathology specific to the lysosomal storage disease. Examples of lysosomal storage diseases include the  
15   following: Fabry disease, caused by a deficiency of  $\alpha$ -galactosidase; Farber disease, caused by a deficiency of ceramidase;  $G_{m1}$  gangliosidosis, caused by a deficiency of  $\beta$ -galactosidase; Tay-Sachs disease, caused by a deficiency of  $\beta$ -hexosaminidase; Niemann-Pick disease, caused by a deficiency of sphingomyelinase; Schindler disease, caused by a deficiency of  $\alpha$ -N-acetylgalactosaminidase; Hunter syndrome, caused by a deficiency of iduronate-2-  
20   sulfatase; Sly syndrome, caused by a deficiency of  $\beta$ -glucuronidase; Hurler and Hurler/Scheie syndromes, caused by a deficiency of iduronidase; I-Cell/San Fillipo syndrome, caused by a deficiency of mannose 6-phosphate transporter; and Gaucher disease, caused by a deficiency of human glucocerebrosidase (GC).

Gaucher disease is the most common lysosomal storage disease in the human population and is discussed herein as merely an example of the need to provide replacement therapy of appropriate lysosomal enzyme to the corresponding lysosomal enzyme deficiency disease.

5           Gaucher disease is caused by a deficiency of GC activity, which hydrolyzes the  $\beta$ -glycosidic linkage between the ceramide and glucose moieties of glucocerebroside. This glycolipid cannot be catabolyzed at a sufficient rate in patients with Gaucher disease due to the decreased enzymatic activity and thus, accumulates in reticuloendothelial cells of the bone marrow, spleen, and liver. Complications of Gaucher disease include bone marrow  
10 expansion, bone deterioration, hypersplenism, hepatomegaly, thrombocytopenia, anemia, and lung disorders. Three clinical forms of Gaucher disease have been described to date: type 1 (adult, non- neuronopathic), type 2 (infantile, acute neuronopathic), and type 3 (juvenile, subacute neuronopathic). Gaucher disease, an autosomal recessive disease, is most prevalent in the Ashkenazi Jewish population, where one in eighteen is a carrier. Over five thousand  
15 people in the United States alone are afflicted with this disease, 99% of whom are considered to have the type 1 clinical form.

          The current treatment for Gaucher disease involves the replacement of the deficient GC with active GC, made possible with the knowledge of the GC sequence and recombinant DNA technology (Tsuji et al., 1986; Sorge et al., 1985; Sorge et al., 1986). Administering  
20 exogenous GC, termed enzyme replacement therapy, has significantly improved the lives of many Gaucher patients. Enzyme replacement therapy reduces the symptomatic effects of Gaucher disease and reverses the hepatic, splenic, and hematologic manifestations of the disease (Pastores et al., 1993).

Unfortunately, the benefits from enzyme replacement therapy are costly. At this time, there are only two methods for commercially producing clinically effective, purified human GC. The first method involves purifying GC from pooled human placentae, currently produced by Genzyme Corporation as Ceredase™. Approximately 500 to 2000 kilograms of placenta (equivalent to 2,000-8,000 placentae) are required to treat each Gaucher disease patient every two weeks. (Radin, U.S. Patent 5,929,304).

Interestingly, placental GC does not possess optimal pharmacokinetic properties for treating Gaucher disease. Because glycoproteins are cleared from the circulation and differentially taken up by various cell types through plasma membrane receptors, producing GC with N-glycan terminal sugars that favor uptake into the target cells results in a more effective distribution of GC. Deposits of glucocerebroside in Gaucher patients are found in non-parenchymal cells, such as Kupffer cells and macrophages, but not in parenchymal cells, such as hepatocytes. The non-parenchymal cells do not preferentially take up native placental GC. The existence of ubiquitous mannose-recognizing receptors on macrophage membranes (Kawasaki et al., 1978; Baynes and Wold 1976; Stahl et al., 1978) suggested that GC with at least one exposed mannose residue could be differentially targeted to phagocytic cells to achieve therapeutic effect. Sequential removal of NeuAc, Gal, and GlcNAc residues from the native human placental GC by the enzymatic activity of neuraminidase, galactosidase, and N-acetylglucosaminidase (Furbish et al., 1981) generated modified GC with terminal mannose residues that had a significantly increased rate of clearance from the circulation and increased specific uptake by Kupffer cells. The increased effectiveness of the remodeled GC is believed to be due to the exposure of terminal mannose residues, the removal of sialic acid residues (which decrease the rate of clearance of glycoproteins), and

the removal of N-glycan terminal galactose residues (which preferentially direct glycoproteins to cells containing galactose receptors, such as hepatocytes) (Ashwell and Morell, 1974). As a result of this research, the commercial preparation of clinically effective GC involves remodeling of native GC as described by Furbish et al., 1981.

5           A second method of commercially producing GC, which eliminates the safety concerns associated with GC isolated from human tissue, involves *in vitro* cell culture. Genzyme Corporation produces Cerezyme™ from Chinese hamster ovary cells transformed with a plasmid encoding a human GC DNA sequence (Rasmussen et al., U.S. Patent No. 5,236,838, hereinafter the '838 patent). The carbohydrate chains of GC produced in this  
10          system must be remodeled in the same way that the placental GC is remodeled to render the final GC product clinically effective.

Carbohydrate remodeling of GC into its clinically effective form is a time-consuming and expensive process. This process requires sequential application of three enzymes to create N-glycans with terminal mannose residues that convert the placental GC or the CHO-  
15          synthesized GC into its clinically effective form. Both methods are expensive: the approximate cost of treating a 50 kilogram patient with Gaucher disease is \$70,000 to \$300,000 per year (Radin, supra). Currently, there is no commercially employed method to produce clinically effective GC in animal cells without the time-consuming and expensive process of carbohydrate remodeling. Because of its crucial role in determining GC clinical  
20          efficacy, it is worthwhile to consider the process of human protein glycosylation.

To better understand the carbohydrate remodeling process, a brief overview of human glycosylation is presented herein. Proteins synthesized in mammalian cells destined for secretion or transport to the Golgi, lysosomes, or plasma membrane, are covalently modified

with carbohydrates in the endoplasmic reticulum and Golgi apparatus. The addition of such carbohydrates to proteins facilitate *in vivo* functionality by directing localization of the mature glycoprotein and, in some cases, inducing correct protein conformation. The process of protein glycosylation begins with the transfer of a preformed oligosaccharide containing 14 sugar residues comprised of N-acetylglucosamine, mannose, and glucose from dolichol to specific asparagine residues of the protein. Next, glycosidases may remove glucose and mannose residues in the endoplasmic reticulum. In the Golgi apparatus, the protein may be left unmodified, leaving N-glycans described as the "high mannose," type or the protein may be further processed by the addition of more sugars, resulting in N-glycans described as "complex" oligosaccharides. Complex oligosaccharides include sialic acid, fucose, galactose, mannose 6-phosphate, and N-acetylglucosamine residues.

The process of endogenous GC glycosylation follows the same pattern as other lysosomal enzymes. The glycosylation of human placental GC results in a mature GC with an apparent molecular mass of 66 kDa due to glycosylation at four of five consensus sequences for asparagine-linked glycosylation. One of these sites must be glycosylated to confer enzymatic activity, thus requiring GC production in a eukaryotic system. Approximately 25% of the N-glycans of placental GC are of the high-mannose type with the remaining N-glycans being the complex type.

Despite the difficulty of producing clinically effective GC, there are examples of recombinant GC being produced in heterologous systems. For example, the baculovirus expression system can be harnessed to produce GC in virally infected insect cell lines (Ginns et al., U.S. Patent No. 6,074,864, hereinafter the '864 patent). Ginns reported that this expression system yielded 2.2 mg of GC per liter. The majority of the GC produced by this

system and in the baculovirus system studied by Grabowski et al., (1989) was found to be cell associated. In addition to the very low yield of GC produced by the method of the '864 patent, numerous disadvantages to the expression system of the '864 patent exist. First, because the host insect cells are killed at the end of each infection cycle, GC expression is only transient, requiring constant infections of new cells in order to continuously produce GC. In order to constantly infect new cells, large stocks of two cell lines must be cultured: one cell line must be maintained to infect and express GC, and the second cell line must be maintained to generate virus. Second, the biological authenticity of expressed protein is not guaranteed, because the cell machinery necessary for post-translational modifications in insect cells is inactivated in the late stages of infection. This leads to an increase in the heterogeneity of the expressed GC and an apparent molecular mass ranging from 52 kDa to 67 kDa ('864 patent). For this reason, the amount of clinically effective GC produced by the '864 patent may actually be lower than the yield reported. Third, the purification of recombinant GC from virally-infected insect cells is inconvenient, requiring detergent-mediated extraction and a complex purification scheme. The low GC yield, inefficient GC secretion, and complicated purification scheme are all major disadvantages of the baculovirus-expression system claimed in the '864 patent.

The '838 patent claims a CHO-expression system comprising a recombinant GC at least 95% identical to an amino acid sequence of primate GC. The expression system described in the '838 patent discloses both baculovirus-infected insect cells and transfected mammalian cells (CHO cells) to express recombinant GC. According to the '838 patent, one to ten milligrams of recombinant GC per liter of CHO cells was recovered. In the CHO expression system, the recombinant GC was detected intracellularly after extraction with

detergent and in the growth media, indicating that only a portion of the GC was secreted into the growth media. The GC harvested from within the cells had a lower molecular weight and was sensitive to endoglucosaminidase H and endoglucosaminidase F, indicating the intracellular GC was of the high mannose type. Conversely, the secreted GC was resistant to endoglucosaminidase H. Cerezyme<sup>TM</sup>, which is produced by this method, differs from placental GC by the presence of a histidine in place of arginine at position 495 of the mature GC and by the absence of any high mannose type N-glycans.

Recombinant GC, produced by the method of the '838 patent, also requires remodeling as described by Furbish et al., (1981) to be clinically effective. The remodeled recombinant GC and placental GC were found to have different cell type distributions *in vivo* with approximately twice as much recombinant GC reaching the targeted Kupffer cells (Friedman, U.S. Patent No. 5,549,892, hereinafter the '892 patent). The increased clinical efficacy of the recombinant GC was attributed to either the small difference in the amino acid sequence or to differences in carbohydrate composition. The carbohydrate structure of the CHO-expressed GC has a greater number of fucose and N-acetylglucosamine residues than the remodeled placental GC.

In the Radin patent (U.S. Patent No. 5,929,304, hereinafter the '304 patent), an expression system to produce GC and  $\alpha$ -L-iduronidase in transgenic tobacco plants is claimed. In the method of the '304 patent, the GC is expressed as its naturally occurring sequence or with an antibody-specific epitope. The purification of GC from the plant requires harvesting the plant and extracting the membrane-associated GC in a laborious and potentially costly process involving detergent extraction. Not only is the process for GC purification labor-intensive, but also as another disadvantage of this system, differences exist between the



glycosylation patterns in plants and humans that will affect the clinical efficacy of plant-expressed GC (Doran, 2000). Unlike humans, plant glycoproteins do not contain  $\alpha$ 1,6-fucose residues linked to the innermost N-acetylglucosamine residue. *In vivo*,  $\alpha$ 1,6-fucosylation protects N-glycans against hydrolysis by glycoasparaginase (Noronkoski et al., 1997), thus, protecting the mannose terminated N-glycans that are important for GC's clinical efficacy. In addition, plant N-glycans contain a plant specific  $\beta$ 1,2-xylose residue attached to the  $\beta$ -linked mannose residue of the core N-glycan (Staudacher et al., 1999), which is known to be highly immunogenic and may be allergenic (van Ree et al., 2000). Thus, plants have not been considered appropriate candidates for the expression of therapeutic lysosomal enzymes due to their glycosylation profile (Altmann, 1997; Bakker et al., 2001). The apparent increase in molecular mass of plant-produced GC was reported in the '304 patent to be 8 kDa, in contrast to Cerezyme's<sup>TM</sup> molecular mass increase of 4.8 kDa, indicating yet another difference between Cerezyme<sup>TM</sup> and plant-produced GC having unknown consequences.

Studies have shown that most of the insect cell lines used for recombinant protein expression are unable to perform complex glycosylation due to the lack of, or limited expression of galactosyltransferases and sialyltransferases, enzymes that are involved in complex N-glycan synthesis (Takahashi et al., 1999; Hollister and Jarvis, 2001). Therefore, endogenous insect cell proteins contain little or no complex types of N-glycans (Kubelka et al., 1994). Also, when the baculovirus-insect cell expression system is used for producing recombinant glycoproteins, little or no detectable N-glycans containing terminal sialic acid are found (Kulakosky et al., 1998). The inability of insect cells to perform complex glycosylation, which has been considered a limitation for expressing glycoproteins in this system (Altmann, 1997), is actually an advantage for expressing lysosomal enzymes intended

for therapeutic purposes. Because insect-produced proteins predominantly contain paucimannose type N-glycans (Kulakosky et al., 1998; Takahashi et al., 1999), with at least one non-reduced terminal mannose residue, the insect cell expression system eliminates the need for the time-consuming and costly enzymatic remodeling steps that are required to produce clinically effective GC isolated from other eukaryotic cells, such as CHO cells.

In the Iatrou patent (U.S. Patent No. 5,759,809, hereinafter the '809 patent), a method for enhancing heterologous protein production in insect cells is claimed. In order to increase heterologous protein production, the insect cells are transfected with a plasmid encoding, in addition to the protein desired, genetic elements including an insect cell promoter and a baculovirus enhancer. The plasmid may also encode the baculoviral IE-1 gene product, a general transcriptional regulator. Either through infection or transfection, the expression cassette can direct insect cells to synthesize the desired protein in large quantities. This patent is incorporated herein by reference. However, the '809 patent does not teach the production of clinically effective lysosomal enzymes.

A need exists for a simple expression system that can provide an abundant supply of GC in its clinically effective form without the complication and cost associated with carbohydrate chain remodeling. Recombinant GC can be produced at low levels using several genetically engineered organisms, but clinically effective GC must contain N-glycans with terminal mannose sugars, requiring expression in a eukaryotic organism. Because the majority of heterologous GC produced in eukaryotic organisms is membrane-associated, a complex purification is required to prepare GC from the cells. A much better approach for efficiently producing clinically effective GC in a heterologous expression system is to engineer an expression vector for a system that will produce high levels of mature GC in a

soluble and clinically effective form.

The heterologous expression system described herein secretes mature, clinically effective GC at a high yield without the need for carbohydrate remodeling. Therefore, the main advantages of the expression system described herein for GC are (1) the expression of GC in a stably transformed expression system; (2) a consistently higher level of GC expression than in baculovirus or mammalian cell expression systems; (3) production of GC in a soluble form secreted to the media; and (4) proper glycosylation modifications for GC, requiring no enzymatic carbohydrate remodeling to be clinically effective. This expression system described and claimed herein provides for a more effective, economical, and simpler approach to manufacturing recombinant GC.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a flow diagram of expression vector pIE1/153A.GC-B construction. The plasmid labeled pBLSKm is the pBluescript<sup>®</sup>SK(-) plasmid (Stratagene, Genbank Accession No. X52324). The crosshatched regions on the depicted vectors denoted "Amp<sup>R</sup>" encode a gene that confers ampicillin resistance. The lightly dappled regions on the depicted vectors denoted "ColE1 origin" and "f1 origin" are replication origins recognized by *Escherichia coli*. Plasmid pBLSKm-GC1a containing human GC cDNA sequences depicted as the plain white region encodes human GC (Tsuji et al., 1986) and was obtained as the I.M.A.G.E. Consortium CloneID 512548 from the TIGR/ATCC Special Collection of human cDNA clones (Lennon et al., 1996). Plasmid pBLSKm-GC1a was sequenced to ensure that the coding region for GC corresponded to the published GC sequence (Tsuji et al., 1986). The plain white region denoted "GC1a (*Bam*H1, *Hind*III)" encodes human GC as exemplified from nucleotide 94 to nucleotide 1492 of SEQ ID NO:1. The plain white region denoted

PCRGcwt2 (*Bam*HI, *Sph*I) is from pBLSKm-PCRGcwt2 (FIG. 2), contains the sequence as exemplified in SEQ ID NO:1 from nucleotide 1489 to nucleotide 1571, encodes human GC as exemplified in SEQ ID NO:2 from amino acid 493 to amino acid 516 and was ligated to the *Bam*HI end of the "GC1a (*Bam*HI, *Hind*III)" fragment to form the C-terminal end of GC.

- 5 Oligonucleotides having the sequences of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11 were annealed and ligated together to encode the GC secretion signal and eight amino acid residues of the mature GC N-terminus as exemplified in SEQ ID NO:12. The resulting fragment was ligated to the *Hind*III end of the "GC1a (*Bam*HI, *Hind*III)" fragment to form the amino-terminal end of GC. The plain white region denoted "GC" encodes human GC protein as exemplified by SEQ ID NO:2. The expression vector pIE1/153A contains a pBluescript® SK(+) backbone (Genebank Accession No. X52325), denoted as the pBLSKp backbone, and elements for high expression (Lu et al., 1997). The dotted regions on the depicted vectors denoted "actin" and "actin promoter" are the actin gene and actin gene promoter from the *Bombyx mori* genome. The single hatched regions on the depicted vectors denoted "HR3 element" is the 1.2 kB enhancer from the *Bombyx mori* NPV genome. The darkened regions on the depicted vectors denoted "IE1 gene" is the immediate early gene from the *Bombyx mori* genome.

FIG. 2 is a flow diagram of the construction of two different vectors using PCR:

- pBLSKm-PCRGcwt2 and pBLSKm-PCRGcsr2, both encoding human GC. Plasmid pBLSKm-GC1a containing human GC cDNA sequences depicted as the plain white region and labeled "GC cDNA" encodes human GC (Tsuji et al., 1986) and was obtained as the I.M.A.G.E. Consortium CloneID 512548 from the TIGR/ATCC Special Collection of human cDNA clones (Lennon et al., 1996). Plasmid pBLSKm-GC1a was sequenced to ensure that

the coding region for GC corresponded to the published GC sequence (Tsuji et al., 1986). The plasmid labeled pBLSKm is the pBluescript®SK(-) plasmid from Stratagene (Genbank Accession No. X52324). Plasmid pBLSKm-GC1a and primers SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7 were used during PCR to remove 3' non-coding sequences and to add cloning sites. The sequences of the fragments generated by PCR were confirmed to be correct by nucleotide sequencing. The sequence of the *Bam*HI, *Sph*I fragment from pBLSKm-PCRCwt2 encoding the 24 C-terminal amino acid residues of human GC reported by Tsuji et al. (1986) can be found in SEQ ID NO:1 from nucleotide 1489 to nucleotide 1571. The sequence of the *Bam*HI, *Sph*I fragment from pBLSKm-PCRCsr2 encoding the 24 C-terminal amino acid residues of human GC reported by Sorge et al. (1985; 1986; Genbank Accession No. M16328) can be found in SEQ ID NO:3 from nucleotide 1489 to nucleotide 1571. The crosshatched regions on the depicted vectors denoted "Amp<sup>R</sup>" encode a gene that confers ampicillin resistance. The lightly dappled regions on the depicted vectors denoted "ColE1 origin" and "f1 origin" are replication origins recognized by *E. coli*.

FIG. 3 is a comparison of the carboxy-terminal ends of two sequences for human glucocerebrosidase. Note the difference in amino acid position 514, which is arginine in SEQ ID NO:2 and histidine in SEQ ID NO:4, encoded by SEQ ID NO:1 and SEQ ID NO:3, respectively.

FIG 4 is a bar graph demonstrating that both expression vectors encoding SEQ ID NO:1 and SEQ ID NO:3 direct enzymatically active GC production and secretion in all three cell lines, Bm5, High Five™, and Sf21. Bm5, High Five™, and Sf21 cells were transfected with pIE1/153A.GC-B (containing SEQ ID NO:1), pIE1/153A.GC-C (containing SEQ ID NO:3), and pIE1/153A (the vector without insert). Media aliquots from each cell population

were tested for  $\beta$ -glucosidase activity. The asterisk indicates that the Bm5 cell population containing the vector without insert expressed essentially zero GC activity.

FIG. 5 is a Western blot comparing the molecular mass of GC secreted (lanes 5-7) into serum-free media or maintained intracellularly (lanes 11-13) to that of Cerezyme™.

5 High Five™ cells were transfected with the pIE1/153A.GC-B containing SEQ ID NO:1 (lanes A), pIE1/153A.GC-C containing SEQ ID NO:3 (lanes B), and the vector without insert, pIE1/153A (lanes C). After growing for three days in serum-free media, 10.0  $\mu$ L samples of media and extracts from 25,000 cells were resolved on a 9% SDS-PAGE gel, transferred by Western blotting, and probed with the GC-specific antibody NN1274.

10 FIG. 6 is a graph of GC activity secreted by three cell lines, each produced by single cell clones transformed with the GC-encoding plasmid pIE1/153A.GC-B. At each time period designated, aliquots of media were tested for GC activity.

FIG. 7 is a Coomassie® Blue stained SDS-PAGE gel of media aliquots from culture supernatants of Bm5, High Five™, and Sf21 cells either untransformed (denoted by "-"), or  
15 transformed (denoted by "+") with the GC-encoding plasmid pIE1/153A.GC-B. 4.0  $\mu$ L of media aliquots were taken at the days indicated on the figure from Bm5 and Sf21 culture supernatants whereas 2.0  $\mu$ L was taken from High Five™ culture supernatants and loaded on the gel. The amounts of Cerezyme™ indicated on the figure were loaded for comparison. The samples were resolved on a 9% SDS-PAGE gel.

20 FIG. 8 is a Western blot of media aliquots from culture supernatants of Bm5, High Five™, and Sf21 cells either untransformed (denoted by "-"), or transformed (denoted by "+") with the GC-encoding plasmid pIE1/153A.GC-B. 2.0  $\mu$ L of media aliquots were taken at the days indicated on the figure from Bm5 and Sf21 culture supernatants whereas 1.0  $\mu$ L

was taken from High Five™ culture supernatants and loaded on the gel. The amounts of Cerezyme™ indicated on the figure were loaded for comparison. The samples were resolved on a 9% SDS-PAGE gel, transferred by Western blotting, and probed with the GC-specific antibody NN1274.

## 5 SUMMARY OF INVENTION

One aspect of the invention is a pharmaceutical composition comprising clinically effective GC produced by an insect expression system, wherein the insect cells are transformed with a vector encoding GC. The vector that encodes GC may contain SEQ ID NO:1 or SEQ ID NO:3. The vector may optionally encode a secretion signal, as exemplified  
10 by amino acids 1-19 of SEQ ID NO:12. Additionally, the vector may include a promoter sequence and an enhancer sequence functionally linked to the expression of GC. An exemplary promoter region is the actin gene promoter from the *Bombyx mori* genome. An exemplary enhancer region is the 1.2 kB enhancer from the *Bombyx mori* NPV genome. The vector may also encode a general transcriptional regulator, such as the IE-1 gene from the  
15 *Bombyx mori* genome. Insect cells that may be part of the expression system include those from the species of *Bombyx mori*, *Spodoptera frugiperda*, or *Trichoplusia ni*. The clinically effective GC produced by the insect expression system possesses asparagine-linked terminal mannose residues.

Yet another aspect of the invention is a method for treating individuals with  
20 deficiencies in GC, wherein the method includes introducing into these individuals clinically effective recombinant GC produced by insect cells.

A further aspect of the invention is an expression system that is comprised of an insect cell transformed with a vector encoding GC that produces clinically effective GC. The

vector that encodes GC may contain SEQ ID NO:1 or SEQ ID NO:3. The vector may optionally encode a secretion signal, as exemplified by amino acids 1-19 of SEQ ID NO:12. Additionally, the vector may include a promoter sequence and an enhancer sequence functionally linked to the expression of GC. An exemplary promoter region is the actin gene promoter from the *Bombyx mori* genome. An exemplary enhancer region is the 1.2 kB enhancer from the *Bombyx mori* NPV genome. The vector may also encode a general transcriptional regulator, such as the IE-1 gene from the *Bombyx mori* genome. Insect cells that may be part of the expression system include those from the species of *Bombyx mori*, *Spodoptera frugiperda*, or *Trichoplusia ni*. The clinically effective GC produced by the insect expression system possesses asparagine-linked terminal mannose residues.

Yet another aspect of the invention is a method of producing clinically effective GC comprising the steps of developing a vector that encodes GC, introducing the developed vector into at least one cell that is capable of receiving the vector and as acting as host to the vector, nurturing the insect cell that contains the vector so the GC is transcribed and

translated in its clinically effective form, and recovering the insect cell-produced GC. The vector that encodes GC may contain SEQ ID NO:1 or SEQ ID NO:3. The vector may optionally encode a secretion signal, as exemplified by amino acids 1-19 of SEQ ID NO:12. Additionally, the vector may include a promoter sequence and an enhancer sequence functionally linked to the expression of GC. An exemplary promoter region is the actin gene promoter from the *Bombyx mori* genome. An exemplary enhancer region is the 1.2 kB enhancer from the *Bombyx mori* NPV genome. The vector may also encode a general transcriptional regulator, such as the IE-1 gene from the *Bombyx mori* genome. Insect cells that may be part of the expression system include those from the species of *Bombyx mori*,



*Spodoptera frugiperda*, or *Trichoplusia ni*. The clinically effective GC produced by the insect expression system possesses asparagine-linked terminal mannose residues.

Furthermore, another aspect of the invention is a method of producing clinically effective GC comprising the steps of creating a vector that encodes GC with a signal

5 sequence for secretion functionally linked to an enhancer and a promoter, wherein the vector also encodes a structural gene that enhances transcription as well as a structural gene that is a detectable marker, introducing the created vector into an insect cell, growing the insect cell, synthesizing and secreting clinically effective GC under conditions favorable for growth and replication, and collecting the secreted, recombinantly synthesized, and clinically effective

10 GC. The vector that encodes GC may contain SEQ ID NO:1 or SEQ ID NO:3. The vector may optionally encode a secretion signal, as exemplified by amino acids 1-19 of SEQ ID NO:12. Additionally, the vector may include a promoter sequence and an enhancer sequence functionally linked to the expression of GC. An exemplary promoter region is the actin gene promoter from the *Bombyx mori* genome. An exemplary enhancer region is the 1.2 kB

15 enhancer from the *Bombyx mori* NPV genome. The vector may also encode a general transcriptional regulator, such as the IE-1 gene from the *Bombyx mori* genome. Insect cells that may be part of the expression system include those from the species of *Bombyx mori*, *Spodoptera frugiperda*, or *Trichoplusia ni*. The clinically effective GC produced by the insect expression system possesses asparagine-linked terminal mannose residues.

## 20 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

This section provides a general discussion of preferred methodologies to develop preferred transfected cells and vectors, which includes, but is not limited to, the preferred components of expression cassettes containing lysosomal enzymes (for example, GC), and

the overall process of producing clinically effective lysosomal enzymes. The methodologies are merely presented to enable those skilled in the art of molecular biology to reproduce the claimed invention. Other methodologies can be used as known by those skilled in the art, as long as the resulting expression system produces a clinically effective lysosomal enzyme (for example, GC) in a sufficient quantity to be applied pharmaceutically.

The present invention relates to a heterologous expression system capable of expressing a lysosomal enzyme that is clinically effective in a significant quantity. The expression system is comprised of a transfected insect cell, wherein the insect cell is transfected with a vector containing an expression cassette encoding a human lysosomal enzyme. The expression cassette of the transfection vector has, in addition to a coding sequence of a human lysosomal enzyme, genetic elements to support a high level of expression. Genetic elements, nucleotide sequences, may initiate transcription, increase transcription, or encode peptides for localization. The transfection vector used to create the expression system of the current invention also encodes a detectable marker to differentiate transfected insect cells from non-transfected insect cells. The expression system herein described results in the secretion of clinically effective human lysosomal enzyme secretion into the insect cell's extracellular environment. The expression system of the current invention is capable of producing a clinically effective lysosomal enzyme at unprecedented levels, making the process highly efficient.

More specifically, the invention relates to expression cassettes containing promoters and enhancers identified from insects, a recombinant expression cassette containing a DNA sequence representing a lysosomal enzyme gene functionally linked to an insect cellular promoter, transplacement fragments containing recombinant expression cassettes, vectors

having transplacement fragments, and enhancer components and stable lines of various insect cells. To provide for a better understanding of the invention, certain definitions are provided as follows:

An “expression system” is defined specifically herein as a heterologous expression system that includes an insect cell containing the elements of the vector encoding a lysosomal enzyme, already defined above. The expression system results in the secretion of a clinically effective lysosomal enzyme into the insect cell’s extracellular environment. The expression system of the current invention is capable of producing clinically effective lysosomal enzyme at unprecedented levels, making the process highly efficient.

A “vector” is defined herein as a nucleic acid composition that includes the expression cassette and DNA sequences that provide for replication and selection preferably in bacteria (e.g. *E. coli*) for amplification. In addition to the expression cassette, the vector may also encode for other gene products. The vector may be a plasmid.

An “expression cassette” is defined herein as a nucleotide sequence encoding from its 5’ to 3’ direction: (1) a promoter sequence; (2) a signal sequence for secretion; and 3) a nucleotide coding sequence for a lysosomal enzyme. A preferred sequence is GC. The expression may optionally include an enhancer. The sequences for all of the elements are functionally linked to one another. The expression cassette is capable of directing the expression and secretion of a lysosomal enzyme in its active form. Additionally, and as known to those in the art, the expression system can include additional nucleic acid sequences for terminating transcription and additional nucleic acid sequences for initiating and terminating translation.

The “promoter” is defined herein as a DNA sequence that initiates and directs the

transcription of a heterologous gene into an RNA transcript in cells. The promoter can be any DNA sequence that initiates and directs transcription. For example, the promoter may be a mammalian promoter such as the cytomegalovirus immediate early promoter, the SV40 large T antigen promoter, or the Rous Sarcoma virus (RSV) LTR promoter. Alternatively, the promoter may be derived from an insect cell, such as the actin gene promoter from *Bombyx mori*, the ribosomal gene promoter, the histone gene promoter, or the tubulin gene promoter.

A "signal sequence" is defined herein as a nucleotide sequence that encodes an amino acid sequence that initiates transport of a protein across the membrane of the endoplasmic reticulum. Additionally, signal sequences could initiate peptide secretion. A signal sequence localizes a synthesized protein. Although other signal sequences could be used, an amino acid sequence of an exemplary signal sequence for GC is given by amino acid residues 1-19 of SEQ ID NO:12.

An "enhancer" is defined herein as any nucleic acid that increases transcription when functionally linked to a promoter regardless of relative position (for example, a cis-acting enhancer). An exemplary enhancer for GC expression is a 1.2 kB BmNPV enhancer region defined in the '809 patent.

"Functionally linked" is defined herein as the influential relationship between two or more nucleotide regions. For example, the actin gene promoter is functionally linked to a lysosomal enzyme gene if it controls the transcription of the gene and it is located on the same nucleic acid fragment as the gene. In another example, an enhancer is functionally linked to a lysosomal enzyme gene if it enhances the transcription of that gene and it is located on the same nucleic acid fragment as the gene.

Other protein products that could be encoded by the vector include detectable markers and transcription regulators. "Detectable markers" are defined herein as genes that allow for the detection of cells that contain the elements of the vector defined above over cells which do not. Detectable markers include reporter genes and selection genes. A reporter gene  
5 encodes a foreign protein not required for cell survival. Suitable reporter genes include the gene encoding for green fluorescent protein and the  $\beta$ -galactosidase gene. Like reporter genes, a selection gene encodes a foreign protein required for cells to live under certain conditions. As an example, selection genes encode antibiotic resistance. Other gene products that could be encoded by the vector may confer functionality. For example, the IE-1 protein  
10 of nuclear polyhedrosis viruses (Huybrechts et al., 1992 or Genbank Accession No. X58442) or the herpes simplex virus VP 16 transcriptional activator are proteins that may be included on the vector to promote the expression level.

"Secrete" or "secretion" is defined herein as the active export of lysosomal enzyme from a host cell into the extracellular environment. Secretion occurs through a secretory  
15 pathway in the host cell. For example, in eukaryotic host cells, secretion involves the endoplasmic reticulum and Golgi apparatus cellular components.

"Transcription" is defined herein as the biosynthesis of an RNA molecule from a DNA template strand. The sequence of the synthesized RNA molecule is complementary to the sequence of the DNA template strand.

20 "Transfection" as defined herein refers to a technique for introducing purified nucleic acid into cells by any number of methods known to those skilled in the art. These methods include, but are not limited to, electroporation, calcium phosphate precipitation, cationic lipids, DEAE dextran, liposomes, receptor-mediated endocytosis, particle delivery, and

injection. Cells can be transfected using an appropriate introduction technique known to those in the art (e.g., liposomes). In a preferred embodiment of the invention described herein, the vector is introduced into the insect cells by mixing the DNA solution with Lipofectin<sup>TM</sup> (GIBCO BRL) and adding the mixture to the cells.

5           “Transformation” as defined herein refers to the insertion of introduced DNA into the genome of the organism in which the DNA was introduced.

          “Translation” is defined herein as the linking of amino acids carried by transfer RNA molecules in an order specified by the order of the codons along a messenger RNA molecule. The product of translation is a protein.

10           “Insect cells” is defined herein as any living insect cell of any species. In a preferred embodiment of the invention described herein, the insect cells from the species *Bombyx mori*, *Spodoptera frugiperda*, and *Trichoplusia ni* were used. Although the use of insect cells is preferred, it is to be understood that any cell line able to express and secrete lysosomal enzymes (for example, GC) in their clinically effective forms can be used.

15           “Clinically effective” as defined herein describes lysosomal enzymes that function as well or better than native lysosomal proteins in patients deficient in the endogenous lysosomal enzyme.

## **GENERAL PREPARATIONS AND METHODOLOGIES**

### General DNA Manipulation

#### 20   *Competent Cell Preparation*

General methodologies disclosed herein are well known to those who practice in the field of molecular biology. Additionally, there are many published sources for the general methods described herein (for example, Ausubel et al, eds., 1988) There are many different

methods known in the art for preparing competent cells for transformation. One example of preparing competent cells for transformation preferably involves the following steps. *E. coli* strain HB101 (Boyer and Roulland-Dossoix, 1969) is streaked onto a LB plate and incubated at approximately 37°C for approximately fifteen hours. A single colony is inoculated into 2.0 mL of LB and cultured at approximately 37°C for approximately eight hours. The culture is then inoculated into 100.0 mL of LB and shaken vigorously until the culture reaches between 0.3 to 0.5 OD<sub>600</sub>. The culture is chilled on ice for approximately ten minutes and the cells recovered by centrifugation at approximately 4,000 rpm for approximately ten minutes in a Sorval GS3 rotor. The pellet is then resuspended in 50.0 mL of ice-cold 0.1 M MgCl<sub>2</sub> and stored on ice for approximately twenty minutes. The cells are again pelleted and resuspended in 5.0 mL 0.1 M CaCl<sub>2</sub> and incubated on ice for approximately one hour. The suspension is mixed with 1.15 mL of 80% glycerol, and 100.0 µL aliquots are then rapidly frozen on dry ice and stored at approximately -70°C for later use.

#### *Purification of DNA Fragments*

There are many different methods known in the art for purifying nucleic acid fragments. One example of purifying nucleic acid fragments is discussed herein in the context of the lysosomal enzyme, GC. Preferably, to isolate GC-coding DNA fragments, a restriction enzyme digested DNA or PCR sample is loaded onto an agarose gel and the fragments resolved by electrophoresis is known in the art. A gel slice containing the band representing the GC gene is cut out and sealed in 8,000 MWCO dialysis tubing with 500.0 µL ddH<sub>2</sub>O. The tubing is placed in an electrophoresis tank and electrophoresis continued for fifteen to sixty minutes to elute the GC gene from the gel.

The solution containing the GC-encoding DNA is then collected, extracted with 500.0

μL of both phenol and chloroform: isoamyl alcohol (95:5), and precipitated with 0.25 M ammonium acetate, 2.5 volumes of 95% ethanol, and 10.0 μg yeast tRNA carrier. The nucleic acid is pelleted by centrifugation at 14,000 rpm for ten minutes, rinsed with 70% ethanol, and resuspended in 20.0 μL ddH<sub>2</sub>O.

#### 5 *Ligation*

There are many different methods known in the art for ligating nucleic acid fragments to one another. One example of ligating nucleic acid fragments to one another is described herein in the context of the lysosomal enzyme GC. Preferably, to ligate the GC-encoding gene into a preferred plasmid vector (discussed supra), a 20.0 μL ligation mixture is prepared that contains 50.0-200.0 ng linearized vector, a five- fold molar excess of insert DNA, 1.0 mM ATP, 50.0 mM Tris-HCl (pH 7.6), 10.0 mM MgCl<sub>2</sub>, 1.0 mM DTT, 5% (w/v) PEG 8000, and 1 unit of T4 DNA ligase (Life Technologies). For ligation of cohesive termini, the ligation mixture is incubated at 16°C for a length of time ranging between two to sixteen hours.

#### 15 *Bacterial Transformation*

There are many different methods known in the art for introducing nucleic acids into bacteria. One example of transformation includes the following steps. The transformation of the lysosomal enzyme (for example, GC) expression cassette discussed herein preferably involves gently mixing 10.0 μL of ligation mixture with 100.0 μL freshly thawed competent cells, followed by incubation on ice for approximately thirty minutes. The sample is heat shocked for approximately two minutes at 42°C, then mixed with 900.0 μL of LB, and incubated at 37°C for approximately thirty minutes. The cells are then pelleted by centrifugation at approximately 6,000 rpm, resuspended in 100.0 μL of fresh LB and spread



on a LB agar plate containing 100.0 µg/mL ampicillin. The plate is then incubated overnight at approximately 37°C.

#### *Identification of Recombinant Clones*

There are many different methods known in the art for identifying transformed bacteria clones. One example of identifying recombinant clones includes the following steps. Pre-screening of individual plasmid DNAs presumed to contain a successfully ligated lysosomal enzyme gene is preferably performed using quick minipreps of several colonies. The verification of the plasmid DNAs containing the lysosomal enzyme gene is then preferably undertaken by sequencing or the restriction enzyme digestion pattern of miniprep DNA.

#### *MiniPrep for Plasmid DNA*

There are many different methods known in the art for amplifying, purifying, and identifying nucleic acids transformed into bacteria. One preferred example of amplifying, purifying, and identifying nucleic acid is discussed herein. A single colony of *E. coli* HB 101 transformed with a pBluescript® SK(+/-) based recombinant plasmid (Stratagene, Genbank Accession No. X52324) is inoculated into 2.0 mL LB media containing 100.0 µg/mL of ampicillin and incubated at approximately 37°C overnight. Preferably the following day, 100.0 mL of bacterial culture is pelleted at approximately 3,000 rpm for one minute in a benchtop centrifuge. The pellet is next resuspended in 25.0 µL of ddH<sub>2</sub>O and vortexed vigorously with an equal volume of phenol. After centrifuging for approximately two minutes at 3,000 rpm, 15.0 µL of the supernatant is mixed with 2.5 µL of 6X DNA dye (.25% bromophenol blue, 0.25% xylene cyanol FF and 40% (w/v) glycerol). The mixture is then analyzed on a 1.0% agarose gel for supercoiled plasmid DNA using gel electrophoresis

techniques commonly known in the art. Supercoiled plasmid DNA containing the insert can be easily discriminated from plasmids without the insert because they migrate more slowly during electrophoresis than plasmids without an insert.

An alternative method for preparing mini-prep DNA is to preferably pellet 1.5 mL of  
5 an overnight bacterial culture at approximately 6,000 rpm for five minutes in the benchtop centrifuge and resuspend in 100.0  $\mu$ L of Solution I (which preferably includes 50.0 mM glucose, 25.0 mM Tris-HCl, pH 8.0, and 10.0 mM EDTA, pH 8.0). Next, 200.0  $\mu$ L of freshly prepared Solution II (which preferably includes 0.2 M NaOH and 1.0% SDS) is added and mixed gently to the suspended pellet to cause cell lysis and denature the nucleic acid.

10 After incubating five minutes on ice, 150.0  $\mu$ L of Solution III (which preferably includes 90.0  $\mu$ L of 3 M potassium acetate, 17.25  $\mu$ L of glacial acetic acid, and 47.25  $\mu$ L ddH<sub>2</sub>O) is added and mixed well. The resulting suspension is incubated on ice for approximately five minutes to allow the DNA to renature and the protein-nucleic acid complexes to precipitate.

After centrifuging for five minutes spin at approximately 14,000 rpm in a  
15 microcentrifuge to pellet debris, the supernatant is transferred to a fresh tube, and the aqueous phase containing the nucleic acid is extracted with 500.0  $\mu$ L phenol to remove residual protein. Next the phenol is extracted using 500.0  $\mu$ L of chloroform: isoamyl alcohol (95:5). Nucleic acid consisting of plasmid DNA and bacterial RNA is then precipitated with 1.0 mL of 95% ethanol and pelleted by centrifuging at approximately 14,000 rpm. The pellet is then  
20 rinsed with 70% ethanol and dissolved in 50.0  $\mu$ L ddH<sub>2</sub>O containing 20.0  $\mu$ g/mL DNase-free RNase.

#### *Large Scale Plasmid DNA Preparation*

There are many different methods known in the art for amplifying and purifying

nucleic acids from bacteria. One preferred example of amplifying and purifying nucleic acids from bacteria is discussed herein. For a large-scale preparation of the DNA plasmid, a preferred method includes the following steps. A single colony is incubated for approximately eight hours in 2.0 mL of LB containing 100.0 µg/mL ampicillin and then  
5 transferred into 250.0 mL of terrific broth, which contains 100.0 µg/mL ampicillin. The mixture is then incubated overnight. Preferably the following day, cells are pelleted by centrifugation at approximately 4,500 rpm for approximately ten minutes in a Sorval GS3 rotor. The pellet is then resuspended with 5.0 mL of Solution I (as discussed supra) and incubated for ten minutes with 1.0 mL of 10.0 mM Tris-HCl (pH 8.0) containing 100.0  
10 µg/mL hen egg-white lysozyme. The cells are then lysed and the nucleic acid is denatured for ten minutes by adding 10.0 mL of freshly prepared Solution II, (discussed supra). The DNA is then renatured by adding 7.5 mL of Solution III (discussed supra) and then incubated on ice for approximately twenty minutes. After centrifuging at approximately 8,000 rpm in a SS23 rotor, the supernatant is mixed well with 0.6 volumes of isopropanol and then stored at  
15 room temperature for approximately ten minutes. The nucleic acid from the supernatant is precipitated by centrifuging at around 8,000 rpm for approximately ten minutes in a SS34 rotor, and is subsequently dissolved in 3.0 mL of ddH<sub>2</sub>O.

To further purify the plasmid DNA, 3.3 g of cesium chloride and 200.0 µL of 10.0 mg/mL ethidium bromide can be added. The sample is spun at approximately 8,000 rpm in  
20 an SS34 rotor. The clear supernatant is then loaded into a 3.90 mL ultracentrifuge tube (Beckman Coulter) and centrifuged at approximately 10,000 rpm for at least five hours at 20°C in preferably a TL-100 benchtop ultracentrifuge (Beckman Coulter) equipped with a TLN-100 rotor. After centrifugation, the band containing supercoiled plasmid DNA is

recovered preferably using a 1.0 mL syringe and a 21-gauge needle. Preferably 0.5 mL of solution is collected. The ethidium bromide in the solution can be removed by extraction several times with 1.0 mL of n-butanol saturated with 4.0 mM NaCl and 10.0 mM EDTA until the solution is completely colorless.

- 5           The solution is next diluted with 3 volumes of ddH<sub>2</sub>O, and the plasmid DNA is precipitated using 2.5 volumes of 95% ethanol. After centrifuging at approximately 10,000 rpm for around twenty minutes (preferably using a SS34 rotor), the plasmid DNA is dissolved in ddH<sub>2</sub>O and is preferably precipitated twice using 0.25 M ammonium acetate and 2.5 volumes of 95% ethanol. The pellet is then rinsed with 70% ethanol and dissolved in
- 10 ddH<sub>2</sub>O. The DNA concentration can be determined preferably using a Beckman spectrophotometer with methods well known in the art.

#### *Sequencing Nucleic Acids*

- There are many different methods known in the art for sequencing nucleic acids. One preferred example of sequencing nucleic acids is described herein. Sequencing plasmid DNA
- 15 is preferably performed by PCR using fluorescent dideoxynucleotides. A 10.0 µL solution containing 1.0 µg plasmid template, 50.0 nmol of each primer, and 4.0 µL of MIX (Perkin-Elmer) is subjected to thirty PCR cycles. The PCR cycles include denaturing at 96°C for approximately thirty seconds, annealing at 50°C for approximately thirty seconds, and product extension at 60°C for approximately four minutes. The product is then precipitated
- 20 with 2.5 volumes of 95% ethanol, 0.25 M ammonium acetate, and 10.0 µg yeast tRNA. The dried pellet can then be analyzed using acrylamide gel electrophoresis.

#### *Expression Vector Construction*

There are several different methods known in the art to construct expression vectors.

However, techniques to engineer expression cassettes and transformation vectors typically include standard in vitro genetic recombination and manipulation. Vectors for the expression of human GC in insect cells were preferably constructed as shown in FIG. 1. The GC expression vector, pIEI/153A.GC-B, containing the native GC structural gene exemplified in

5 SEQ ID NO:1 and encoding native human GC (SEQ ID NO:2) was constructed by the insertion of the 1587 bp GC expression fragment (SEQ ID NO:1) into the *Xba*I, *Not*I site of the insect expression vector pIEI/153A (described by Lu et al., 1997) to form the expression vector pIEI/153A.GC-B. Likewise, an expression vector encoding human GC with the C-terminal variant (SEQ ID NO:4; Sorge et al., 1985 and Sorge et al., 1986) was created by

10 inserting the 1587 bp *Xba*I, *Not*I expression fragment (SEQ ID NO:3) from the pBL3m-GCSGSsr2 plasmid into the pIEI/153A expression vector to form the GC expression vector pIEI/153A.GC-C. The structural genes for human GC were constructed from three fragments of DNA generated using oligonucleotides for the N-terminal sequences (FIG. 1), PCR for the C-terminal sequences (FIG. 2), and a plasmid pBLSKm-GC1a (FIG. 1) containing human GC

15 cDNA for the remaining sequences. Where nucleotide sequences were required for recognition and cleavage of particular restriction enzymes, oligonucleotides containing the desired sequence were annealed and ligated to specific denoted sites within the plasmid, as is well known in the art.

Specifically, PCR (FIG. 2) with plasmid pBLSKm-GC1a and primers SEQ ID NO:5,

20 SEQ ID NO:6, and SEQ ID NO:7, were used to add cloning sites, remove 3' non-coding DNA sequences, and to generate two different C-terminal amino acid coding sequences as shown in FIG. 3. SEQ ID NO:1 has a DNA sequence altered from the native sequence but still encoding the native human GC amino acid sequence (SEQ ID NO:2). SEQ ID NO:3

encodes the C-terminal amino acid variant of human GC (Sorge et al., 1985; Sorge et al., 1986). The two sequences differ by only one amino acid. The 83 bp *Bam*HI, *Sph*I PCR-generated regions coding for the two different C-terminal ends of human GC were ligated to the *Bam*HI site of the GC cDNA from the plasmid pBLSKm-GC1a (FIG. 1) in an intermediate vector with a pBluescript®SK(-) backbone (Stratagene, Genbank Accession No. X52324) and appropriate cloning sites to form constructs containing sequences coding for most of the mature GC. Finally, as shown in FIG. 1, a 96 bp *Bsp*DI, *Xba*I fragment constructed from four oligonucleotides, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11 encoding the native GC secretion signal and the missing mature GC N-terminal amino acid sequence was ligated at the *Bsp*DI, *Hind*III sites of the intermediate vectors containing the partial GC coding sequences to give the final GC structural genes of SEQ ID NO:1 and SEQ ID NO:3 contained in the plasmids pBL3m-GCSGCwt2 (FIG. 1) and pBL3m-GCSGCsr2, respectively.

#### Generation of Transfected Insect Cells

##### *Cell Lines*

Three lepidopteran cell lines, Bm5, Sf21, and High Five™ are hosts for the expression system of the invention. However, any suitable cell line could be utilized for the expression vector disclosed herein. Bm5 cells (Dr. Iatrou, University of Calgary, Calgary, Alberta, Canada) were established from the ovarian tissue of the domesticated silkworm *Bombyx mori* according to the procedure of Grace, (1967). Sf21 cells (Invitrogen) were established from the pupal ovarian tissue of the fall armyworm *Spodoptera frugiperda* according to Vaughn et al., (1977). BTI-TN-5B1-4 cells (commonly referred to as High Five™ cells; Invitrogen) were established from egg cell homogenates of the cabbage looper *Trichoplusia ni* according

to Granados et al., (1994). Each of the above protocols describing the respective derivation of the Bm5 cells, Sf21 cells, and High Five<sup>TM</sup> cells are incorporated by reference herein.

#### *Culture Media*

The lepidopteran insect cells lines identified supra are routinely sub-cultured in a preferred IPL-41 insect media (Life Technologies) supplemented with 2.6 g/L tryptose phosphate broth (Difco), 0.35 g/L NaHCO<sub>3</sub>, 0.069 mg/L ZnSO<sub>4</sub>·7H<sub>2</sub>O, 7.59 mg/L AIK(SO<sub>4</sub>)<sub>2</sub>·12H<sub>2</sub>O and 10% fetal bovine serum (JRH Biosciences). The osmotic pressure is adjusted to 370.0 mOsm with 9.0 g/L sucrose, and pH adjusted to 6.2 with 10.0 M NaOH prior to sterile filtering through 0.2 µm filter units. For growth in serum-free media (SFM), a commercial formulation using IPL-41 media, Sf-9000 II SFM (Life Technologies), Ex-Cell<sup>TM</sup> 401 (JRH Biosciences), or ESF921 (Expression Systems LLC) can be used. Preferably, no antibiotics are used in media.

#### *Culture Maintenance*

The lepidopteran cell lines are preferably maintained in CO<sub>2</sub> free incubators at approximately 28°C. Cells are preferably subcultured weekly in 25 cm<sup>2</sup> T-flasks at a dilution factor of 1:5 with fresh media.

To recover frozen cell lines, one cryovial is removed from liquid nitrogen and rapidly thawed in a water bath having an approximate temperature of 28°C. The cells are then placed in a 25 cm<sup>2</sup> T-flask with 4.0 mL fresh media, and allowed to adhere for approximately five hours at approximately 28°C. The culture media containing DMSO and dead cells is then replaced with 5.0 mL fresh media.

The trypan blue exclusion method (Freshney, 1997) is preferably used to estimate the cell density and viability of cell cultures. This method is based on the fact that viable cells

are impermeable to trypan blue, whereas dead cells are permeable to the dye. Typically, a cell culture sample is diluted 1:3 with 0.1% trypan blue in phosphate buffered saline (PBS; 10 mM  $\text{KH}_2\text{PO}_4$ , 2 mM  $\text{NaH}_2\text{PO}_4$ , 140 mM NaCl, 40 mM KCl), and samples counted at least twice in a hemocytometer. Although the above methods are preferred, any skilled artisan would recognize that the conditions for cell line growth, maintenance, and manipulation depend upon the cell lines used and therefore could vary within the scope of the invention.

#### *Transfection of Insect Cells*

Transfection of the cell lines identified supra with the vector identified supra could be accomplished in a variety of ways, all of which are well understood in the art. The following protocol is the preferred method for transfecting the insect cells of the expression system disclosed herein. The transfer of the expression vector comprising the expression cassette for a lysosomal enzyme into cultured insect cells is preferably performed using a cationic liposome compound commonly referred to as Lipofectin™ (Life Technologies). These positively charged liposomes are attracted to negatively charged DNA. Insect cells to be transfected are prepared by dilution in fresh media to a density of  $5 \times 10^5$  viable cells/mL, and transferring 2.0 mL of the cell suspension to each well of a six-well tissue culture plate (35.0 mm diameter, Falcon), to allow adherence overnight. A transfection solution is then prepared containing 30.0 µg/mL Lipofectin™ (Life Technologies) and 6.0 µg/mL total plasmid DNA in basal IPL-41. The lipid is initially diluted in 0.275 mL IPL-41 (Life Technologies) and incubated for forty-five minutes at room temperature. The plasmid DNA is diluted separately in 0.275 mL basal IPL-41 and then combined with the Lipofectin™ solution. The resulting solution is incubated on ice for approximately fifteen minutes. The cells are then washed twice with 1.0 mL basal IPL-41 and incubated at approximately 28°C with 0.55 mL



transfection solution per well. After approximately six hours of transfection, the cells are rinsed with basal IPL-41 followed by adding 2.0 mL complete media to the well.

Approximately three days later, samples can be analyzed for transfection.

#### Detection and Analysis of Recombinantly Produced GC

##### 5 *Preparation of Total Cell Extracts for SDS-PAGE*

Anyone skilled in the art will recognize that there are a variety of ways to prepare cellular extracts for SDS-PAGE. The preferred method for preparing cellular extracts for SDS-PAGE is discussed herein. Transfected insect cells are counted forty-eight to sixty hours post-transfection and pelleted at around 3,000 rpm for approximately five minutes in a microcentrifuge. The transfected cells are then washed two times with 1.0 mL of PBS.

Aliquots containing  $2 \times 10^5$  viable cells are pelleted and resuspended in 40.0  $\mu$ L ddH<sub>2</sub>O and 8.0  $\mu$ L 6X SDS-PAGE sample buffer. The viscosity of the samples can be reduced by mild sonication for approximately ten seconds to shear nucleic acid. Samples were boiled for 3 minutes before loading on gels.

##### 15 *Protein Quantitation, SDS-PAGE, Western Blot Analysis, and Amino Acid Sequencing*

Detection and quantitation of recombinantly produced GC is preferably performed using protein assays, SDS-PAGE and Western blot analysis. These techniques are well-known to those skilled in the art. See for example, Coligan, et al., eds. (1989).

SDS-PAGE was performed on samples to be analyzed by amino acid sequence analysis. After transferring to PVDF membranes, proteins were stained with 0.1% Coomassie<sup>®</sup> Blue R250. Bands containing the protein of interest were excised. Amino acid sequence analysis was accomplished using an Applied Biosystems Procise 492 cLC system. Optimized standard pulsed-liquid phase cycles were used. The Coomassie<sup>®</sup> Blue stained

membrane strip was cut into approximately 2.0 mm pieces and loaded into the cartridge for analysis.

Western blot analysis can be performed in different ways, as anyone skilled in the art knows. The preferred method for detecting recombinantly produced lysosomal enzyme by

5 Western blot analysis is discussed herein in the context of GC. Sample aliquots containing recombinant proteins are resolved by electrophoresis in a SDS-containing 9% acrylamide gel (SDS-PAGE), and electroblotted onto nitrocellulose Hybond-ECL (Amersham) or Immobilon™-P membranes (Millipore Corporation) overnight at 30 V in the cold. After the transfer, the filter is blocked for one hour at room temperature in 50.0 mL PBS-0.1% Tween-  
10 20 (PBST) containing 10% (w/v) skim milk powder (PBSTM). The filter is then incubated for one hour at room temperature with 5.0 mL PBST containing GC-specific polyclonal antibody obtained from Dr. Ernst Beutler, Scripps Clinic and Research Foundation, La Jolla, California and designated NN1274. The filter is then washed twice for approximately fifteen minutes with PBST, and incubated one hour with 5.0 mL PBSTM containing horseradish  
15 peroxidase-conjugated species goat anti-rabbit IgG. After washing twice with PBST, the filter is incubated with ECL chemiluminescent substrate (Amersham) according to the supplier's instructions and exposed to X-ray film. Alternatively, an ImmunoBlot Assay Kit (Bio-Rad Laboratories) containing goat anti-rabbit phosphatase, BCIP, and NBT can be used.

#### *β - glucosidase Assay*

20 There are a variety of protocols that could be employed to detect the activity of a recombinantly expressed lysosomal enzyme. In the context of detecting GC activity, an exemplary method to detect the GC activity is the β-glucosidase assay (adapted from Suzuki, 1978, which is incorporated herein by reference). Other enzyme assays to detect the activity

of other lysosomal enzymes may be used. With respect to GC activity, the  $\beta$ -glucosidase assay is a widely utilized assay in Gaucher disease research and is carried out under conditions in which other, non-GC glucosidase activities are partially inhibited, i.e., by using a phosphate buffer, pH 5.9, 0.125 % taurocholate, 0.15 percent Triton X-100. In this assay, the fluorometric product, 4-methylumbelliferone (4-MU) is enzymatically released from the substrate, 4-methylumbelliferyl- $\beta$ -D-glucopyranoside (4MUG) by GC. Samples and controls are first serially diluted on ice in 1X Assay Buffer (40.0 mM phosphate citrate buffer pH 5.90, 0.15% Triton X-100, and 0.12% sodium taurocholate) and 20.0  $\mu$ L of each sample is added to sample wells of a 96-well plate (Nunc) already containing 30.0  $\mu$ L of 1X Assay Buffer. Then 50.0  $\mu$ L of substrate (2 mM 4-MUG in 1 X assay Buffer) is added to sample wells and after gentle shaking, the enzymatic reaction is allowed to proceed at approximately 37°C. After approximately thirty minutes to one hour, the reaction is stopped by the addition of 150.0  $\mu$ L Stop Solution (0.6 M glycine pH10.7). Next, 150.0  $\mu$ L aliquots of standard containing 0 to 16,000  $\mu$ M 4-MU in Stop Solution and 100.0  $\mu$ L of 1 X Assay Buffer are added to standard wells. The amount of fluorometric product, 4-MU is detected by measuring the 465 nm emission from wells excited at 360 nm using a HTS7000 fmax Fluorescence Microplate Reader (Molecular Devices). Linear regression of standard measurements allowed the estimation of GC activity in culture samples. One unit of GC activity (U) is defined as the amount of enzyme required to hydrolyze one micromole of 4-methylumbelliferyl- $\beta$ -D-glucopyranoside (4-MUG) per minute at 37°C. Examples of this assay regarding GC expression are provided at FIG. 6 and discussed infra.

**Example 1: Transient expression of native human GC**

The expression plasmids pIEI/153A.GC-B and pIEI/153A.GC-C were generated by

digesting the plasmids pBL3m-GCSGCwt2 and pBL3m-GCSGCsr2 with the restriction enzymes *XbaI* and *NotI* and inserting the nucleotide fragment encoding for the GC gene (SEQ ID NO:1 or SEQ ID NO:3) into the unique *XbaI*, *NotI* sites of the pIE1/153A plasmid (Lu et al., 1997). This vector directs a high level of expression of heterogenous proteins

5 through the use of the insect actin promoter, a trans-acting transcription activator, and a transcriptional enhancer. FIG. 1 illustrates the process of expression vector production. To confirm insertion and correct orientation, the 5'- and 3'- ends of the GC gene were sequenced. The different human GC genes on each of pBLSKm-PCRGCwt2 and pBLSKm-PCRGCsr2 (FIG. 2) have a one amino acid difference, as exemplified in FIG. 3. The  
10 sequence encoding human GC in the *BamHI*, *SphI* pBLSKmPCRGCwt2 fragment can be found in SEQ ID NO:1 from nucleotide 1489 to 1560. The sequence encoding human GC in the *BamHI*, *SphI* pBLSKm-PCRGCsr2 fragment can be found in SEQ ID NO:3 from nucleotide 1489 to 1560. The amino acid at position 514 of SEQ ID NO:2 is arginine, whereas the amino acid at position 514 of SEQ ID NO:4 is histidine. Methods to construct  
15 vectors are well known in the art and exemplified supra.

Bm5 (Dr. Iatrou), Sf21 (Invitrogen), and High Five<sup>TM</sup> (Invitrogen) insect cells were transfected with the GC-encoding expression plasmid pIE1/153A.GC-B (described above), pIE1/153A.GC-C (described above), and the control plasmid pIE1/153A, which lacked the coding region for GC. The transfection protocol was described by Farrell et. al., (1998),  
20 which is incorporated herein by reference. Initial transfections were performed in media containing approximately 10% fetal bovine serum.  $\beta$ -glucosidase activity assays were used to quantitate the amount of GC secreted to the media three days post-transfection. The results are summarized in FIG. 4.  $\beta$ -glucosidase activity was observed in all three cells lines

transfected with vectors encoding the native GC sequence (pIEI/153A.GC-B containing SEQ ID NO:1) or the C-terminal variant GC sequence (pIEI/153A.GC-C containing SEQ ID NO:3). The High Five<sup>TM</sup> cells produced the greatest amount of GC activity followed by the Bm5 cells and Sf21 cells, respectively.

5           Three days post-transfection samples of insect cell extracts and supernatants were analyzed by Western blotting. The Western blots revealed that each cell line, independent of the GC sequence or cell type, efficiently secreted GC. After three days, approximately five-fold more GC had accumulated in the media than was present inside the transfected cells. Due to co-migration of GC with the large amount of bovine serum albumin present in the  
10           supernatant, no accurate measurement of the molecular mass of the secreted GC could be obtained. However, the insect-produced GC of either the native or variant sequence co-migrated with Cerezyme<sup>TM</sup> (Genzyme), indicating all three proteins have similar molecular masses.

          To estimate the molecular mass of the GC secreted by insect cells, High Five<sup>TM</sup>, Bm5,  
15           and Sf21 cells were transfected with the GC expression plasmids pIEI/153A.GC-B and pIEI/153A.GC-C and the cell populations were maintained in EXCELL 401 serum-free media for three days. Western immunoblot analysis of media aliquots and cell extracts demonstrated that the molecular mass of the native or variant GC produced in insect cells was substantially the same as Cerezyme<sup>TM</sup> at approximately 59 kDa, and was independent of the  
20           insect cell line. GC remaining intracellularly had a molecular mass of 61.5 kDa. Insect cells in serum-free media efficiently secreted GC with five to ten-fold more GC in the media than in the cells. Results from the High Five<sup>TM</sup> cells are shown in FIG. 5. This efficiency of secretion was surprising, because human GC is not secreted extracellularly and in previous

work with the baculovirus-insect cell expression system the majority of the expressed GC was found to be cell-associated ('864 patent; Grabowski, 1989). This efficient secretion of GC by insect cells is an advantage over most GC expression systems, allowing for simplified purification procedures.

## 5    **Example 2: GC Expression from Polyclonal Populations**

To generate stably transformed insect cell lines, two antibiotic selection schemes were tested, both well established in the art:

1) Co-transfection of the expression plasmids with pBmA.HmB (Dr. Iatrou, University of Calgary, Calgary, Alberta, Canada), a selection plasmid expressing hygromycin  
10    B phosphotransferase, enables cells with successful integration events to survive in the presence of the antibiotic hygromycin B. The procedure for selecting stable cell lines using hygromycin B is discussed in Farrell et. al., (1998).

2) Co-transfection of the expression plasmids with pBmA.PAC (Dr. Iatrou, University of Calgary, Calgary, Alberta, Canada), a selection plasmid expressing puromycin  
15    acetyltransferase, enables cells with successful integration events to survive in the presence of the antibiotic puromycin.

Bm5, High Five<sup>TM</sup>, and Sf21 cells were transfected in 6-well plates with a 100:1 molar ratio of expression cassette to antibiotic selection plasmid. After 48 hours recovery in non-selective conditions, the culture media was exchanged with selective media containing  
20    antibiotic. Subculturing and media exchanges were performed each week until a polyclonal population of antibiotic resistant cells was obtained and transferred to a 25 cm<sup>2</sup> T-flask. GC production by polyclonal populations decrease as faster growing, less productive clones within the population eventually dominate. Regardless of selection scheme, the polyclonal

populations of Bm5, High Five<sup>TM</sup>, and Sf21 cells all have the ability to express the GC protein.

Samples from each polyclonal population were taken 7 days after transformation and analyzed by a  $\beta$ -glucosidase assay to estimate the GC levels. The results demonstrate that the polyclonal populations of Bm5, High Five<sup>TM</sup>, and Sf21 cells all have the ability to express native or C-terminal variant GC, independent of the antibiotic selection scheme.  $\beta$ -glucosidase levels ranged from 7-38 U/L. Activity in the negative control cells ranged from 0.4-2 U/L.

SDS-PAGE analysis and detection by Coomassie<sup>®</sup> Blue staining revealed that a band of 59 kDa is produced only in the transformed polyclonal populations. Cerezyme<sup>TM</sup> also migrated as a 59kDa band, but had a slightly greater heterogeneity. Western immunoblot analysis confirmed that this expressed band is GC and is only present in the transformed cells. N-terminal amino acid sequence analysis of the 59 kDa band seen in the transformed insect cells confirmed its identity as GC and that insect cells are able to cleave the human GC secretion signal to produce mature GC starting at amino acid 20 (SEQ ID NO:2) as is seen for mature human GC.

### **Example 3: GC Expression From Single Clones**

#### *Selection of clones*

Co-transfection of plasmids encoding GC with plasmids encoding hygromycin B phosphotransferase or puromycin acetyltransferase created populations of GC expressing Sf21, High Five<sup>TM</sup>, and Bm5 cells resistant to either puromycin and hygromycin. All populations were transfected in the presence of a 100:1 molar ratio of GC expression encoding plasmid to antibiotic resistance encoding plasmid. After culturing for two days in

nonselective media, cells were selected for hygromycin or puromycin resistance.

Clones of Sf21, High Five<sup>TM</sup>, and Bm5 cells expressing GC were isolated by two rounds of limited dilution cloning. In this method, cells from all populations were diluted in selective media and plated at a density of one cell / well in 96-well plates. Cells from single colony wells were reseeded and allowed to grow in selective media for 10 days, after which relative GC activity in the supernatant was determined from the  $\beta$ -glucosidase assay. Clones were chosen based on their high GC activity and proliferation rate and reseeded into 24-well plates. Ten days later clones were assayed for GC activity and clones with the highest GC activity and proliferation were chosen for further expansion and reseeded into 6-well plates.

The most active GC expressing clones from each cell line under each selectable marker were transferred to T-flasks. GC activity was determined in culture supernatant by the  $\beta$ -glucosidase assay after 7 days growth. Cells at this stage were subjected to a second round of limited dilution cloning as above. The final highest producing clones were adapted to suspension cultures in serum-free media.

#### *Production of GC*

High-level production of GC by single cell clones of insect cells was demonstrated by measuring GC activity in the supernatants of suspension cultures over time. The  $\beta$ -glucosidase assay was employed to quantitate the activity of the GC produced by the transformed Bm5, High Five<sup>TM</sup>, and Sf21 single cell clones. The  $\beta$ -glucosidase assay was performed as described supra. In FIG. 6, the GC activity from media was assayed daily 3-10 days after transfection. The activity level of the Bm5 produced GC peaked at day 10, whereas the activity level of the High Five<sup>TM</sup> produced GC peaked at day 9. Peak activity of the Sf21 produced GC occurred at day 6. The High Five<sup>TM</sup> clones produced the highest level



of GC followed by the Bm5 and Sf21 clones. Typically, 200-300 U/L, 100-150 U/L, and 50-100 U/L were observed in the High Five<sup>TM</sup>, Bm5, and Sf 21 clones, respectively. This activity was determined to be from GC, because no more than 2 U/L of endogenous glucosidase activity was seen for any untransformed cell line.

5       Coomassie<sup>®</sup> Blue stained SDS-PAGE gels, as exemplified in FIG. 7, demonstrated a 59 kDa band that co-migrated with Cerezyme<sup>TM</sup> and was present only in the culture supernatants of cells transformed with GC expression vectors. Typically, a secreted expression level of 25-100 mg/L was demonstrated.

Western immunoblot analysis, as exemplified in FIG. 8, using GC specific polyclonal  
10       antibody confirmed that GC is produced in all three transformed cell lines and is secreted to the media as a 59 kDa protein that co-migrates with Cerezyme<sup>TM</sup>. However, Cerezyme<sup>TM</sup> is slightly more heterogeneous in size than is insect-expressed GC. The molecular mass of GC predicted by either the native (SEQ ID NO:2) or variant (SEQ ID NO:4) GC amino acid sequence is 55.6 kDa. Recombinant GC produced in CHO cells has only complex  
15       oligosaccharide chains added to only four of the five N-glycosylation sites ('892 patent). Complete remodeling of this structure would result in a protein with a maximum molecular mass of approximately 60.6 kDa. The High Five<sup>TM</sup> clones gave the highest level of GC production, followed by the Bm5, and Sf 21 clones. By comparison to the Cerezyme<sup>TM</sup> standard it was estimated that, typically, GC levels of 25-100 mg/L were produced.

## 20       *Purification*

Methods to purify recombinant proteins are well known to those of skill in the art. In the case of the recombinantly expressed lysosomal enzyme GC, most GC sources, such as transformed CHO cells, baculovirus-infected insect cells, or human placental tissue, require

detergent for solubilization because GC is associated with the cellular fraction. In contrast, GC produced with the expression system herein described is secreted into the extracellular environment at high concentrations in a soluble form permitting a less time-consuming purification procedure to be utilized.

- 5           One non-limiting method to purify GC from the media of suspension cultures of transformed insect cells is described herein. The media containing GC is separated from cells by centrifugation and can be stored at -80°C until further purification is desired. All chromatography steps are done at 4°C. After thawing, the media is clarified by centrifugation and filtered before applying to a Hi Prep 16/10 octyl-sepharose hydrophobic interaction
- 10   column (Pharmacia) using a model 2150 high-pressure liquid chromatography system (LKB-Produkter AB). The column is equilibrated in Buffer A (50 mM Nacitrate buffer, pH 6.0; pH adjusted at room temperature). The column is washed and eluted with a linear 20 to 50% ethanol gradient in Buffer A. Eluent from the column is collected fractionally in polypropylene tubes. The fractions are analyzed for activity and purity using the  $\beta$ -
- 15   glucosidase assay and SDS-PAGE, respectively. Fractions with the highest purity and activity are pooled and concentrated using YM-30 membrane concentration devices (Amicon Inc.). The concentrated pool is then further purified by high-pressure liquid chromatography using gel permeation chromatography with a 0.75 x 60 cm TSK G 3000SW column (Tosoh Corporation) equilibrated in Buffer A containing 40% ethanol. Eluent from the column is
- 20   collected fractionally in polypropylene tubes. The fractions are analyzed for activity and purity using the  $\beta$ -glucosidase assay and SDS-PAGE, respectively. Fractions with the highest purity and activity are pooled and concentrated as before. The pooled concentrate is then stored at -80°C. Substantially pure enzyme is obtained.

*Monosaccharide and N-glycan Analysis Regarding the Lysosomal Enzyme GC and Cerezyme™*

Purified GC from a single cell clonal population of High Five™ cells and Cerezyme™ were analyzed by high pH anion-exchange chromatography coupled to pulsed amperometric detection (HPAEC-PAD) to determine the nature and quantity of sialic acid, monosaccharide, and amino-sugars. For the release and quantitation of neutral and amino-sugars, samples were hydrolyzed in 2 N HCl (4 hours, 100°C). For the release and quantitation of sialic acids, samples were hydrolyzed in 0.1 N TFA (1 hour, 80°C). After hydrolysis, samples were dried in a SpeedVac centrifugal evaporator, without heat. Following resuspension in water, the solutions of released monosaccharides were separated on a Dionex PA-1 anion-exchange column. Detection by pulsed amperometry was with a Dionex ED40 electrochemical detector employing a standard pulse waveform (triple potential) optimized for carbohydrate response. Standard curves for quantitation were generated from known amounts of monosaccharides. The identities of monosaccharides in the samples were assigned based on their retention time relative to standard peak retention times. GC produced in insect cells transformed with the pIE1/153A.GC-B vector contained only mannose, N-acetylglucosamine, and fucose residues, demonstrating that complex and O-linked oligosaccharide chains do not exist on insect-produced GC. Because the GC produced by the method described herein lacks sialic acid and galactose residues, it has proportionately more terminal mannose residues, making it more bioavailable to the targeted phagocytic cells. Total monosaccharide analysis was also performed on Cerezyme™ and in contrast to the GC produced by the method described herein, was found to contain a small amount of sialic acid (0.2 mole/mole of protein), indicating incomplete remodeling.

The N-glycan structure of insect cell-expressed recombinant GC was analyzed by Endo H digestion and Western immunoblot analysis. The endoglycosidase, Endo H, specifically releases N-linked hybrid and high mannose type oligosaccharides. If a glycoprotein contains a high mannose structure, the Endo H digestion will lead to a shift in the mobility of the Endo H digested glycoprotein by SDS-PAGE analysis. When insect-produced recombinant GC samples were digested with Endo H as recommended by the manufacturer (Glyko, Inc.), and analyzed by SDS-PAGE and Western immunoblot, no difference in mobility between undigested and Endo H treated GC samples was observed. This demonstrates that the major portion of GC produced by the method described herein does not contain the high mannose type of N-glycan. Proteins with the high mannose type of N-glycan have proportionately fewer terminating mannose residues than proteins without the high mannose type of N-glycan. Because the terminal mannose residues mediate bioavailability in the cells that accumulate glucocerebroside, the lack of these chains in GC produced by the method described herein makes it a more effective product than GC isolated from human placenta (the '838 patent) and from baculovirus production systems (the '864 patent; Martin et al., 1988).

Terminal mannose residues in the N-glycans of GC produced by the method herein were detected by digestion with exoglycosidases  $\alpha$ -mannosidase II and  $\alpha$ -mannosidase VI and Western blot analysis.  $\alpha$ -mannosidase II (MANase II, Glyko, Inc.) has a broad specificity, cleaving  $\text{Man}\alpha 1-2,3$  and 6 linkages, but does not cleave a single  $\text{Man}\alpha 1-6$  linked to the core  $\beta$ -mannose residue.  $\alpha$ -mannosidase VI (MANase VI, Glyko, Inc.) specifically cleaves unbranched  $\text{Man}\alpha 1-6$  linked to the core  $\beta$ -mannose residue. The amount of  $\alpha$ -mannose that can be removed from a glycoprotein by sequential digestion with  $\alpha$ -

mannosidase II and  $\alpha$ -mannosidase VI is directly related to the amount of terminal mannose in the N-glycans. The amount of  $\alpha$ -mannose in recombinant GC samples was determined by Western blotting using a biotinylated Hippastrum Hybrid Lectin (Vector Laboratories) that specifically binds to  $\alpha$ -mannose residues according to the manufacturer's enclosed protocol.

5 Specifically, purified GC samples at 0.45 mg /ml were digested as recommended by the manufacturer (Glyko, Inc.) with mannosidase II at a final concentration of 50 Units/ml for 19 hrs at 37°C. Next, half of the mannosidase II-digested GC sample was further digested with mannosidase VI as recommended by the manufacturer (Glyko, Inc.) at a final concentration of 20 Units/ml for 23 hrs at 37°C. 60 ng of single or double mannosidase digested GC  
10 samples, undigested GC samples, and Cerezyme<sup>TM</sup> were analyzed by Western blotting. The results demonstrated that greater than 95% of  $\alpha$ -mannose residues were removed from recombinant insect-expressed GC by the sequential digestion with  $\alpha$ -mannosidase II and  $\alpha$ -mannosidase VI indicating that almost all the  $\alpha$ -mannose residues of recombinant insect GC as it is directly produced are contained in N-glycan chains that have a terminal mannose  
15 residue and are not located in chains that terminate in other sugars, i.e. sialic acid, galactose, or N- acetylglucosamine residues. Duplicate blots analyzed using GC specific polyclonal antibody confirmed that the decrease in the lectin binding to the mannosidase digested samples was not due to a loss of GC.

The  $\alpha$ -mannose residues present in GC produced by the method disclosed herein are  
20 not contained in high mannose type N-glycans and are not blocked by N-acetylglucosamine residues, sialic acid residues, nor galactose residues. A high proportion of terminal mannose residues is thought to be critical for uptake of GC into the non-parenchymal cells that accumulate glucocerebroside, such as macrophages or Kupffer cells. The high proportion of

terminal  $\alpha$ -mannose residues of the recombinant GC produced directly by the transformed insect cells makes this production system particularly useful and efficient in comparison to systems that require enzymatic remodeling of GC by the sequential digestion of three glycosidases to expose terminal mannose residues.

#### **Patents**

U.S. Patent No. 5,236,838 Rasmussen, et al.

U.S. Patent No. 5,549,892 Friedman, et al.

U.S. Patent No. 5,759,809 Iatrou, et al.

U.S. Patent No. 5,929,304 Radin, et al.

U.S. Patent No. 6,074,861 Ginns, et al.

#### **Other Publications**

Altmann (1997) "More than silk and honey--or, can insect cells serve in the production of therapeutic glycoproteins?" *Glycoconj.J.* **14**, 643-646.

Ashwell et al. (1974) "The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins." *Adv.Enzymol.Relat.Areas.Mol.Biol.* **41**, 99-128.

Ausubel et al. eds., (1988) *Current Protocols in Mol. Biol.*, Vol. I, Chapters 1-3; Vol. III, Chapters 15 and 16, Greene Pub. Associates ; Wiley-Interscience, New York.

Bakker et al. (2001) "Galactose-extended glycans of antibodies produced by transgenic plants." *Proc.Natl.Acad.Sci.U.S.A.* **98**, 2899-2904.

Baynes et al. (1976) "Effect of glycosylation on the in vivo circulating half-life of ribonuclease." *J Biol.Chem.* **251**, 6016-6024.

Boyer et al. (1969) "A complementation analysis of the restriction and modification of DNA

in *Escherichia coli*." *J Mol. Biol.* **41**, 459-472.

Coligan et al. eds., (1995) *Current Protocols in Protein Science*, Vol. I, Chapters 3 and 10, Greene Pub. Associates; Wiley-Interscience: New York.

Doran et al. (2000) "Foreign protein production in plant tissue cultures."

*Curr. Opin. Biotechnol* **11**, 199-204.

Farrell et al. (1998) "High-level expression of secreted glycoproteins in transformed lepidopteran insect cells using a novel expression vector" *Biotechnol. Bioeng.* **60**, 656-663.

Freshney et al. eds., (1994) *Culture of Animal Cells: A Manual of Basic Technique*, pp288-289, Wiley-Liss, Inc., New York.

Furbish et al. (1981) "Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation" *Biochim. Biophys. Acta* **673**, 425-434.

Grabowski et al. (1989) "Expression of functional human acid beta-glucosidase in COS-1 and *Spodoptera frugiperda* cells." *Enzyme* **41**, 131-142.

Grace (1967) "Establishment of a line of cells from the silkworm *Bombyx mori*." *Nature* **216**, 613.

Granados et al. (1994) "A new insect cell line from *Trichoplusia ni* (BTI-Tn-5B1-4) susceptible to *Trichoplusia ni* single enveloped nuclear polyhedrosis virus."

*J. Invertebr. Pathol.* **64**, 260-266.

Hollister et al. (2001) "Engineering lepidopteran insect cells for sialoglycoprotein production by genetic transformation with mammalian beta1,4-galactosyltransferase and alpha2,6-sialyltransferase genes." *Glycobiology* **11**, 1-9.

Huybrechts et al. (1992) "Nucleotide sequence of a transactivating *Bombyx mori* nuclear polyhedrosis virus immediate early gene." *Biochim. Biophys. Acta* **1129**, 328-330.

- Kawasaki et al. (1978) "Isolation and characterization of a mannan-binding protein from rabbit liver." *Biochem.Biophys Res.Commun.* **81**, 1018-1024.
- Kubelka et al. (1994) "Structures of the N-linked oligosaccharides of the membrane glycoproteins from three lepidopteran cell lines (Sf-21, IZD-Mb-0503, Bm-N)." *Arch.Biochem.Biophys.* **308**, 148-157.
- Kulakosky et al. (1998) "N-glycosylation of a baculovirus-expressed recombinant glycoprotein in three insect cell lines." *In Vitro Cell Dev.Biol.Anim.* **34**, 101-108.
- Lennon et al. (1996) "The I.M.A.G.E. Consortium: an integrated molecular analysis of genomes and their expression." *Genomics* **33**, 151-152.
- Lu et al. (1997) "A baculovirus (Bombyx mori nuclear polyhedrosis virus) repeat element functions as a powerful constitutive enhancer in transfected insect cells" *J.Biol.Chem.* **272**, 30724-30728.
- Martin et al. (1988) "Glycosylation and processing of high levels of active human glucocerebrosidase in invertebrate cells using a baculovirus expression vector." *DNA* **7**, 99-106.
- Noronkoski et al. (1997) "Influence of L-fucose attached alpha 1-->6 to the asparagine-linked N-acetylglucosamine on the hydrolysis of the N-glycosidic linkage by human glycosylasparaginase." *Glycobiology* **7**, 217-220.
- Pastores et al. (1993) "Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months" *Blood* **82**, 408-416.
- Sorge et al. (1985) "Molecular cloning and nucleotide sequence of human glucocerebrosidase cDNA" *Proc.Natl.Acad.Sci.U.S.A.* **82**, 7289-7293.
- Sorge et al. (1986) "Molecular cloning and nucleotide sequence of human glucocerebrosidase



cDNA Correction" *Proc.Natl.Acad.Sci.U.S.A.* **83**, 3567-3567.

Stahl et al. (1978) "Evidence for receptor-mediated binding of glycoproteins, glycoconjugates, and lysosomal glycosidases by alveolar macrophages."

*Proc.Natl.Acad.Sci.U.S.A.* **75**, 1399-1403.

Staudacher et al. (1999) "Fucose in N-glycans: from plant to man." *Biochim Biophys Acta* **1473**, 216-236.

Takahashi et al. (1999) "N-glycan structures of murine hippocampus serine protease, neuropsin, produced in *Trichoplusia ni* cells." *Glycoconj.J* **16**, 405-414.

Tsuji et al. (1986) "Nucleotide sequence of cDNA containing the complete coding sequence for human lysosomal glucocerebrosidase" *J.Biol.Chem.* **261**, 50-53.

van Ree et al. (2000) "Beta(1,2)-xylose and alpha(1,3)-fucose residues have a strong contribution in IgE binding to plant glycoallergens." *J Biol.Chem.* **275**, 11451-11458.

Vaughn et al. (1977) "The establishment of two cell lines from the insect *Spodoptera frugiperda* (Lepidoptera; Noctuidae)." *In Vitro* **13**, 213-217.

## WE CLAIM:

1. A pharmaceutical composition comprising clinically effective recombinant glucocerebrosidase synthesized with an expression system comprised of an insect cell transformed with a vector encoding glucocerebrosidase, wherein the expression system synthesizes clinically effective glucocerebrosidase.
2. The pharmaceutical composition of claim 1, wherein the vector encoding glucocerebrosidase contains SEQ ID NO:1.
3. The pharmaceutical composition of claim 1, wherein the vector encoding glucocerebrosidase contains SEQ ID NO:3.
4. The pharmaceutical composition of claim 1, wherein the vector encoding glucocerebrosidase contains a secretion signal of amino acids 1-19 in SEQ ID NO:12.
5. The pharmaceutical composition of claim 1, wherein the vector encoding glucocerebrosidase also contains genetic elements functionally linked to glucocerebrosidase to enhance the expression of glucocerebrosidase.
6. The pharmaceutical composition of claim 5, wherein a genetic element that enhances the expression of glucocerebrosidase is the actin gene promoter from the genome of *Bombyx mori*.
7. The pharmaceutical composition of claim 5, wherein a genetic element that enhances the expression of glucocerebrosidase is the 1.2 kB enhancer from the genome of *Bombyx mori* NPV.

8. The pharmaceutical composition of claim 5, wherein a genetic element that enhances the expression of glucocerebrosidase is the IE-1 gene from the genome of *Bombyx mori*.
9. The pharmaceutical composition of claim 1, wherein the insect cell is a *Bombyx mori* insect cell.
10. The pharmaceutical composition of claim 1, wherein the insect cell is a *Spodoptera frugiperda* insect cell.
11. The pharmaceutical composition of claim 1, wherein the insect cell is a *Trichoplusia ni* insect cell.
12. The pharmaceutical composition of claim 1, wherein the produced glucocerebrosidase possesses asparagine-linked terminal mannose residues.
13. A method for treating individuals with deficiencies in glucocerebrosidase, wherein the method includes introducing into individuals with deficiencies in glucocerebrosidase recombinantly produced glucocerebrosidase from insect cells, wherein the recombinantly produced glucocerebrosidase is produced by insect cells in a clinically effective form.
14. An expression system comprised of an insect cell transformed with a vector encoding glucocerebrosidase that synthesizes clinically effective glucocerebrosidase.
15. The expression system of claim 14, wherein the vector encoding glucocerebrosidase contains SEQ ID NO:1.
16. The expression system of claim 14, wherein the vector encoding glucocerebrosidase contains SEQ ID NO:3.

17. The expression system of claim 14, wherein the vector encoding glucocerebrosidase contains a secretion signal of amino acids 1-19 in SEQ ID NO:12.
18. The expression system of claim 14, wherein the vector encoding glucocerebrosidase also contains genetic elements functionally linked to glucocerebrosidase to enhance the expression of glucocerebrosidase.
19. The expression system of claim 18, wherein a genetic element that enhances the expression of glucocerebrosidase is the actin gene promoter from the genome of *Bombyx mori*.
20. The expression system of claim 18, wherein a genetic element that enhances the expression of glucocerebrosidase is the 1.2 kB enhancer from the genome of *Bombyx mori* NPV.
21. The expression system of claim 18, wherein a genetic element that enhances the expression of glucocerebrosidase is the IE-1 gene from the genome of *Bombyx mori*.
22. The expression system of claim 14, wherein the insect cell is a *Bombyx mori* insect cell.
23. The expression system of claim 14, wherein the insect cell is a *Spodoptera frugiperda* insect cell.
24. The expression system of claim 14, wherein the insect cell is a *Trichoplusia ni* insect cell.
25. The expression system of claim 14, wherein the produced glucocerebrosidase possesses asparagine-linked terminal mannose residues.

26. A method of producing clinically effective recombinant glucocerebrosidase comprising the steps of:

(a) developing a vector that encodes a gene for glucocerebrosidase;

(b) introducing the vector into at least one insect cell that is capable of receiving the

5 vector and serving as host to the vector;

(c) nurturing the at least one insect cell comprising the vector so that the glucocerebrosidase gene of the vector is successfully transcribed and translated into glucocerebrosidase in its clinically effective form; and

(d) harvesting the glucocerebrosidase.

27. The method of claim 26, wherein the vector additionally encodes an enhancer functionally linked to glucocerebrosidase.

28. The method of claim 26, wherein the vector additionally encodes a promoter functionally linked to glucocerebrosidase.

29. The method of claim 26, wherein the vector additionally encodes a structural gene that increases transcription.

30. The method of claim 26, wherein the vector additionally encodes a secretion signal.

31. The method of claim 26, wherein the glucocerebrosidase gene is SEQ ID NO:1.

32. The method of claim 26, wherein the glucocerebrosidase gene is SEQ ID NO:3.

33. The method of claim 27, wherein the enhancer is 1.2 kB from the *Bombyx mori* NPV genome.

34. The method of claim 28, wherein the promoter is the actin promoter from the genome of *Bombyx mori*.

35. The method of claim 29, wherein the structural gene that increases transcription is the IE-1 gene of the *Bombyx mori* genome.

36. The method of claim 30, wherein the signal sequence causing glucocerebrosidase secretion is amino acids 1-19 of SEQ ID NO:12.

37. The method of claim 26, wherein the insect cell is a *Bombyx mori* insect cell.

38. The method of claim 26, wherein the insect cell is a *Spodoptera frugiperda* insect cell.

39. The method of claim 26, wherein the insect cell is a *Trichoplusia ni* insect cell.

40. The method of claim 26, wherein the produced glucocerebrosidase possesses asparagine-linked terminal mannose residues.

41. A method of producing clinically effective recombinant glucocerebrosidase comprising the steps of:

(a) creating a vector encoding a gene for glucocerebrosidase with a signal sequence for secretion functionally linked to an enhancer and a promoter, wherein the vector  
5 also encodes a structural gene that increases transcription as well as a structural gene that is a detectable marker;

- (b) introducing the vector into an insect cell;
- (c) growing the transformed insect cell under conditions so that it can optimally synthesize and secrete clinically effective glucocerebrosidase and create a
- 10 multitude of cells that can synthesize and secrete clinically effective glucocerebrosidase; and
- (d) collecting recombinantly synthesized clinically effective glucocerebrosidase from the extracellular environment.
42. The method of claim 41, wherein the glucocerebrosidase gene is SEQ ID NO:1.
43. The method of claim 41, wherein the glucocerebrosidase gene is SEQ ID NO:3.
44. The method of claim 41, wherein the signal sequence causing glucocerebrosidase secretion is amino acids 1-19 of SEQ ID NO:12.
45. The method of claim 41, wherein the promoter is the actin promoter from the genome of *Bombyx mori*.
46. The method of claim 41, wherein the enhancer is 1.2 kB from the *Bombyx mori* NPV genome.
47. The method of claim 41, wherein the structural gene that increases transcription is the IE-1 gene of the *Bombyx mori* genome.
48. The method of claim 41, wherein the structural gene that is a detectable marker confers ampicillin resistance.
49. The method of claim 41, wherein the insect cell is a *Bombyx mori* insect cell.

51. The method of claim 41, wherein the insect cell is a *Spodoptera frugiperda* insect cell.
52. The method of claim 41, wherein the insect cell is a *Trichoplusia ni* insect cell.
53. The method of claim 41, wherein the produced glucocerebrosidase possesses asparagine-linked terminal mannose residues.



Fig. 1




Fig. 2

Primers to amplify C-terminal SEQ ID NO:1  
SEQ ID NO:5 and SEQ ID NO:6




Fig. 3

SEQ ID NO:1	-----ATT	CAC	ACC	TAC	CTG	TGG	CGC	CGT	CAA	TGA
SEQ ID NO:2	-----Ile	His	Thr	Tyr	Leu	Trp	Arg	Arg	Gln	
	508	509	510	511	512	513	514	515	516	
SEQ ID NO:3	-----ATT	CAC	ACC	TAC	CTG	TGG	CAT	AGA	CAA	TGA
SEQ ID NO:4	-----Ile	His	Thr	Tyr	Leu	Trp	His	Arg	Gln	
	508	509	510	511	512	513	514	515	516	

Fig. 4




Fig. 5




Fig. 6




Fig. 7





Fig. 8



## SEQUENCE LISTING

<110> Cytoclonal Pharmaceuticals, Inc.  
Berent, Susan

<120> Expression System for Efficiently Producing Clinically Effective  
Lysosomal Enzyme s (Glucocerebrosidase)

<130> 10365/07602

<150> US 60/195,598

<151> 2000-04-06

<160> 12

<170> PatentIn version 3.0

<210> 1

<211> 1592

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (13)..(1563)

<400> 1

ctagaattca aa atg gct ggc tcg tta aca gga ttg ctt cta ctt cag gca	51
Met Ala Gly Ser Leu Thr Gly Leu Leu Leu Leu Gln Ala	
1 5 10	
gtg tcg tgg gca tcc gga gct aga cct tgc atc cct aaa agc ttc ggc	99
Val Ser Trp Ala Ser Gly Ala Arg Pro Cys Ile Pro Lys Ser Phe Gly	
15 20 25	
tac agc tcg gtg gtg tgt gtc tgc aat gcc aca tac tgt gac tcc ttt	147
Tyr Ser Ser Val Val Cys Val Cys Asn Ala Thr Tyr Cys Asp Ser Phe	
30 35 40 45	
gac ccc ccg acc ttt cct gcc ctt ggt acc ttc agc cgc tat gag agt	195
Asp Pro Pro Thr Phe Pro Ala Leu Gly Thr Phe Ser Arg Tyr Glu Ser	
50 55 60	
aca cgc agt ggg cga cgg atg gag ctg agt atg ggg ccc atc cag gct	243
Thr Arg Ser Gly Arg Arg Met Glu Leu Ser Met Gly Pro Ile Gln Ala	
65 70 75	
aat cac acg ggc aca ggc ctg cta ctg acc ctg cag cca gaa cag aag	291
Asn His Thr Gly Thr Gly Leu Leu Thr Leu Gln Pro Glu Gln Lys	
80 85 90	

ttc cag aaa gtg aag gga ttt gga ggg gcc atg aca gat gct gct gct Phe Gln Lys Val Lys Gly Phe Gly Gly Ala Met Thr Asp Ala Ala Ala 95 100 105	339
ctc aac atc ctt gcc ctg tca ccc cct gcc caa aat ttg cta ctt aaa Leu Asn Ile Leu Ala Leu Ser Pro Pro Ala Gln Asn Leu Leu Lys 110 115 120 125	387
tcg tac ttc tct gaa gaa gga atc gga tat aac atc atc cgg gta ccc Ser Tyr Phe Ser Glu Gly Ile Gly Tyr Asn Ile Ile Arg Val Pro 130 135 140	435
atg gcc agc tgt gac ttc tcc atc cgc acc tac acc tat gca gac acc Met Ala Ser Cys Asp Phe Ser Ile Thr Tyr Thr Tyr Ala Asp Thr 145 150 155	483
cct gat gat ttc cag ttg cac aac ttc agc ctc cca gag gaa gat acc Pro Asp Asp Phe Gln Leu His Asn Phe Ser Leu Pro Glu Glu Asp Thr 160 165 170	531
aag ctc aag ata ccc ctg att cac cga gcc ctg cag ttg gcc cag cgt Lys Leu Lys Ile Pro Leu Ile His Arg Ala Leu Gln Leu Ala Gln Arg 175 180 185	579
ccc gtt tca ctc ctt gcc agc ccc tgg aca tca ccc act tgg ctc aag Pro Val Ser Leu Leu Ala Ser Pro Trp Thr Ser Pro Thr Trp Leu Lys 190 195 200 205	627
acc aat gga gcg gtg aat ggg aag ggg tca ctc aag gga cag ccc gga Thr Asn Gly Ala Val Asn Gly Lys Gly Ser Leu Lys Gly Gln Pro Gly 210 215 220	675
gac atc tac cac cag acc tgg gcc aga tac ttt gtg aag ttc ctg gat Asp Ile Tyr His Gln Thr Trp Ala Arg Tyr Phe Val Lys Phe Leu Asp 225 230 235	723
gcc tat gct gag cac aag tta cag ttc tgg gca gtg aca gct gaa aat Ala Tyr Ala Glu His Lys Leu Gln Phe Trp Ala Val Thr Ala Glu Asn 240 245 250	771
gag cct tct gct ggg ctg ttg agt gga tac ccc ttc cag tgc ctg ggc Glu Pro Ser Ala Gly Leu Leu Ser Gly Tyr Pro Phe Gln Cys Leu Gly 255 260 265	819
ttc acc cct gaa cat cag cga gac ttc att gcc cgt gac cta ggt cct Phe Thr Pro Glu His Gln Arg Asp Phe Ile Ala Arg Asp Leu Gly Pro 270 275 280 285	867
acc ctc gcc aac agt act cac cac aat gtc cgc cta ctc atg ctg gat Thr Leu Ala Asn Ser Thr His His Asn Val Arg Leu Leu Met Leu Asp 290 295 300	915
gac caa cgc ttg ctg ctg ccc cac tgg gca aag gtg gta ctg aca gac Asp Gln Arg Leu Leu Leu Pro His Trp Ala Lys Val Val Leu Thr Asp 305 310 315	963

cca gaa gca gct aaa tat gtt cat ggc att gct gta cat tgg tac ctg 1011  
 Pro Glu Ala Ala Lys Tyr Val His Gly Ile Ala Val His Trp Tyr Leu  
 320 325 330

gac ttt ctg gct cca gcc aaa gcc acc cta ggg gag aca cac cgc ctg 1059  
 Asp Phe Leu Ala Pro Ala Lys Ala Thr Leu Gly Glu Thr His Arg Leu  
 335 340 345

ttc ccc aac acc atg ctc ttt gcc tca gag gcc tgt gtg ggc tcc aag 1107  
 Phe Pro Asn Thr Met Leu Phe Ala Ser Glu Ala Cys Val Gly Ser Lys  
 350 355 360 365

ttc tgg gag cag agt gtg cgg cta ggc tcc tgg gat cga ggg atg cag 1155  
 Phe Trp Glu Gln Ser Val Arg Leu Gly Ser Trp Asp Arg Gly Met Gln  
 370 375 380

tac agc cac agc atc atc acg aac ctc ctg tac cat gtg gtc ggc tgg 1203  
 Tyr Ser His Ser Ile Ile Thr Asn Leu Leu Tyr His Val Val Gly Trp  
 385 390 395

acc gac tgg aac ctt gcc ctg aac ccc gaa gga gga ccc aat tgg gtg 1251  
 Thr Asp Trp Asn Leu Ala Leu Asn Pro Glu Gly Gly Pro Asn Trp Val  
 400 405 410

cgt aac ttt gtc gac agt ccc atc att gta gac atc acc aag gac acg 1299  
 Arg Asn Phe Val Asp Ser Pro Ile Ile Val Asp Ile Thr Lys Asp Thr  
 415 420 425

ttt tac aaa cag ccc atg ttc tac cac ctt ggc cac ttc agc aag ttc 1347  
 Phe Tyr Lys Gln Pro Met Phe Tyr His Leu Gly His Phe Ser Lys Phe  
 430 435 440 445

att cct gag ggc tcc cag aga gtg ggg ctg gtt gcc agt cag aag aac 1395  
 Ile Pro Glu Gly Ser Gln Arg Val Gly Leu Val Ala Ser Gln Lys Asn  
 450 455 460

gac ctg gac gca gtg gca ctg atg cat ccc gat ggc tct gct gtt gtg 1443  
 Asp Leu Asp Ala Val Ala Leu Met His Pro Asp Gly Ser Ala Val Val  
 465 470 475

gtc gtg cta aac cgc tcc tct aag gat gtg cct ctt acc atc aag gat 1491  
 Val Val Leu Asn Arg Ser Ser Lys Asp Val Pro Leu Thr Ile Lys Asp  
 480 485 490

cct gct gtg ggc ttc ctg gag aca atc tca cct ggc tac tcc att cac 1539  
 Pro Ala Val Gly Phe Leu Glu Thr Ile Ser Pro Gly Tyr Ser Ile His  
 495 500 505

acc tac ctg tgg cgc cgt caa tga gacgcatgcg gtaccggaat tcagcggcc 1592  
 Thr Tyr Leu Trp Arg Arg Gln  
 510 515

&lt;210&gt; 2

&lt;211&gt; 516



&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

Met Ala Gly Ser Leu Thr Gly Leu Leu Leu Leu Gln Ala Val Ser Trp  
1 5 10 15

Ala Ser Gly Ala Arg Pro Cys Ile Pro Lys Ser Phe Gly Tyr Ser Ser  
20 25 30

Val Val Cys Val Cys Asn Ala Thr Tyr Cys Asp Ser Phe Asp Pro Pro  
35 40 45

Thr Phe Pro Ala Leu Gly Thr Phe Ser Arg Tyr Glu Ser Thr Arg Ser  
50 55 60

Gly Arg Arg Met Glu Leu Ser Met Gly Pro Ile Gln Ala Asn His Thr  
65 70 75 80

Gly Thr Gly Leu Leu Leu Thr Leu Gln Pro Glu Gln Lys Phe Gln Lys  
85 90 95

Val Lys Gly Phe Gly Gly Ala Met Thr Asp Ala Ala Ala Leu Asn Ile  
100 105 110

Leu Ala Leu Ser Pro Pro Ala Gln Asn Leu Leu Leu Lys Ser Tyr Phe  
115 120 125

Ser Glu Glu Gly Ile Gly Tyr Asn Ile Ile Arg Val Pro Met Ala Ser  
130 135 140

Cys Asp Phe Ser Ile Arg Thr Tyr Thr Tyr Ala Asp Thr Pro Asp Asp  
145 150 155 160

Phe Gln Leu His Asn Phe Ser Leu Pro Glu Glu Asp Thr Lys Leu Lys  
165 170 175

Ile Pro Leu Ile His Arg Ala Leu Gln Leu Ala Gln Arg Pro Val Ser  
180 185 190

Leu Leu Ala Ser Pro Trp Thr Ser Pro Thr Trp Leu Lys Thr Asn Gly  
195 200 205

Ala Val Asn Gly Lys Gly Ser Leu Lys Gly Gln Pro Gly Asp Ile Tyr  
210 215 220

His Gln Thr Trp Ala Arg Tyr Phe Val Lys Phe Leu Asp Ala Tyr Ala  
225 230 235 240

Glu His Lys Leu Gln Phe Trp Ala Val Thr Ala Glu Asn Glu Pro Ser  
245 250 255

Ala Gly Leu Leu Ser Gly Tyr Pro Phe Gln Cys Leu Gly Phe Thr Pro  
260 265 270

Glu His Gln Arg Asp Phe Ile Ala Arg Asp Leu Gly Pro Thr Leu Ala  
275 280 285

Asn Ser Thr His His Asn Val Arg Leu Leu Met Leu Asp Asp Gln Arg  
290 295 300

Leu Leu Leu Pro His Trp Ala Lys Val Val Leu Thr Asp Pro Glu Ala  
305 310 315 320

Ala Lys Tyr Val His Gly Ile Ala Val His Trp Tyr Leu Asp Phe Leu  
325 330 335

Ala Pro Ala Lys Ala Thr Leu Gly Glu Thr His Arg Leu Phe Pro Asn  
340 345 350

Thr Met Leu Phe Ala Ser Glu Ala Cys Val Gly Ser Lys Phe Trp Glu  
355 360 365

Gln Ser Val Arg Leu Gly Ser Trp Asp Arg Gly Met Gln Tyr Ser His  
370 375 380

Ser Ile Ile Thr Asn Leu Leu Tyr His Val Val Gly Trp Thr Asp Trp  
385 390 395 400

Asn Leu Ala Leu Asn Pro Glu Gly Gly Pro Asn Trp Val Arg Asn Phe  
405 410 415

Val Asp Ser Pro Ile Ile Val Asp Ile Thr Lys Asp Thr Phe Tyr Lys  
420 425 430

Gln Pro Met Phe Tyr His Leu Gly His Phe Ser Lys Phe Ile Pro Glu  
435 440 445

Gly Ser Gln Arg Val Gly Leu Val Ala Ser Gln Lys Asn Asp Leu Asp  
 450 455 460

Ala Val Ala Leu Met His Pro Asp Gly Ser Ala Val Val Val Val Leu  
 465 470 475 480

Asn Arg Ser Ser Lys Asp Val Pro Leu Thr Ile Lys Asp Pro Ala Val  
 485 490 495

Gly Phe Leu Glu Thr Ile Ser Pro Gly Tyr Ser Ile His Thr Tyr Leu  
 500 505 510

Trp Arg Arg Gln  
 515

<210> 3

<211> 1593

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (13)..(1563)

<400> 3

ctagaattca aa atg gct ggc agc ctc aca ggt ttg ctt cta ctt cag gca	51
Met Ala Gly Ser Leu Thr Gly Leu Leu Leu Leu Gln Ala	
1 5 10	
gtg tcg tgg gca tca ggt gcc cgc ccc tgc atc cct aaa agc ttc ggc	99
Val Ser Trp Ala Ser Gly Ala Arg Pro Cys Ile Pro Lys Ser Phe Gly	
15 20 25	
tac agc tcg gtg gtg tgt gtc tgc aat gcc aca tac tgt gac tcc ttt	147
Tyr Ser Ser Val Val Cys Val Cys Asn Ala Thr Tyr Cys Asp Ser Phe	
30 35 40 45	
gac ccc ccg acc ttt cct gcc ctt ggt acc ttc agc cgc tat gag agt	195
Asp Pro Pro Thr Phe Pro Ala Leu Gly Thr Phe Ser Arg Tyr Glu Ser	
50 55 60	
aca cgc agt ggg cga cgg atg gag ctg agt atg ggg ccc atc cag gct	243
Thr Arg Ser Gly Arg Arg Met Glu Leu Ser Met Gly Pro Ile Gln Ala	
65 70 75	
aat cac acg ggc aca ggc ctg cta ctg acc ctg cag cca gaa cag aag	291
Asn His Thr Gly Thr Gly Leu Leu Leu Thr Leu Gln Pro Glu Gln Lys	
80 85 90	

ttc cag aaa gtg aag gga ttt gga ggg gcc atg aca gat gct gct gct	339
Phe Gln Lys Val Lys Gly Phe Gly Gly Ala Met Thr Asp Ala Ala Ala	
95 100 105	
ctc aac atc ctt gcc ctg tca ccc cct gcc caa aat ttg cta ctt aaa	387
Leu Asn Ile Leu Ala Leu Ser Pro Pro Ala Gln Asn Leu Leu Leu Lys	
110 115 120 125	
tcg tac ttc tct gaa gaa gga atc gga tat aac atc atc cgg gta ccc	435
Ser Tyr Phe Ser Glu Glu Gly Ile Gly Tyr Asn Ile Ile Arg Val Pro	
130 135 140	
atg gcc agc tgt gac ttc tcc atc cgc acc tac acc tat gca gac acc	483
Met Ala Ser Cys Asp Phe Ser Ile Arg Thr Tyr Thr Tyr Ala Asp Thr	
145 150 155	
cct gat gat ttc cag ttg cac aac ttc agc ctc cca gag gaa gat acc	531
Pro Asp Asp Phe Gln Leu His Asn Phe Ser Leu Pro Glu Glu Asp Thr	
160 165 170	
aag ctc aag ata ccc ctg att cac cga gcc ctg cag ttg gcc cag cgt	579
Lys Leu Lys Ile Pro Leu Ile His Arg Ala Leu Gln Leu Ala Gln Arg	
175 180 185	
ccc gtt tca ctc ctt gcc agc ccc tgg aca tca ccc act tgg ctc aag	627
Pro Val Ser Leu Leu Ala Ser Pro Trp Thr Ser Pro Thr Trp Leu Lys	
190 195 200 205	
acc aat gga gcg gtg aat ggg aag ggg tca ctc aag gga cag ccc gga	675
Thr Asn Gly Ala Val Asn Gly Lys Gly Ser Leu Lys Gly Gln Pro Gly	
210 215 220	
gac atc tac cac cag acc tgg gcc aga tac ttt gtg aag ttc ctg gat	723
Asp Ile Tyr His Gln Thr Trp Ala Arg Tyr Phe Val Lys Phe Leu Asp	
225 230 235	
gcc tat gct gag cac aag tta cag ttc tgg gca gtg aca gct gaa aat	771
Ala Tyr Ala Glu His Lys Leu Gln Phe Trp Ala Val Thr Ala Glu Asn	
240 245 250	
gag cct tct gct ggg ctg ttg agt gga tac ccc ttc cag tgc ctg ggc	819
Glu Pro Ser Ala Gly Leu Leu Ser Gly Tyr Pro Phe Gln Cys Leu Gly	
255 260 265	
ttc acc cct gaa cat cag cga gac ttc att gcc cgt gac cta ggt cct	867
Phe Thr Pro Glu His Gln Arg Asp Phe Ile Ala Arg Asp Leu Gly Pro	
270 275 280 285	
acc ctc gcc aac agt act cac cac aat gtc cgc cta ctc atg ctg gat	915
Thr Leu Ala Asn Ser Thr His His Asn Val Arg Leu Leu Met Leu Asp	
290 295 300	
gac caa cgc ttg ctg ctg ccc cac tgg gca aag gtg gta ctg aca gac	963
Asp Gln Arg Leu Leu Leu Pro His Trp Ala Lys Val Val Leu Thr Asp	
305 310 315	

cca gaa gca gct aaa tat gtt cat ggc att gct gta cat tgg tac ctg	1011
Pro Glu Ala Ala Lys Tyr Val His Gly Ile Ala Val His Trp Tyr Leu	
320 325 330	
gac ttt ctg gct cca gcc aaa gcc acc cta ggg gag aca cac cgc ctg	1059
Asp Phe Leu Ala Pro Ala Lys Ala Thr Leu Gly Glu Thr His Arg Leu	
335 340 345	
ttc ccc aac acc atg ctc ttt gcc tca gag gcc tgt gtg ggc tcc aag	1107
Phe Pro Asn Thr Met Leu Phe Ala Ser Glu Ala Cys Val Gly Ser Lys	
350 355 360 365	
ttc tgg gag cag agt gtg cgg cta ggc tcc tgg gat cga ggg atg cag	1155
Phe Trp Glu Gln Ser Val Arg Leu Gly Ser Trp Asp Arg Gly Met Gln	
370 375 380	
tac agc cac agc atc atc acg aac ctc ctg tac cat gtg gtc ggc tgg	1203
Tyr Ser His Ser Ile Ile Thr Asn Leu Leu Tyr His Val Val Gly Trp	
385 390 395	
acc gac tgg aac ctt gcc ctg aac ccc gaa gga gga ccc aat tgg gtg	1251
Thr Asp Trp Asn Leu Ala Leu Asn Pro Glu Gly Gly Pro Asn Trp Val	
400 405 410	
cgt aac ttt gtc gac agt ccc atc att gta gac atc acc aag gac acg	1299
Arg Asn Phe Val Asp Ser Pro Ile Ile Val Asp Ile Thr Lys Asp Thr	
415 420 425	
ttt tac aaa cag ccc atg ttc tac cac ctt ggc cac ttc agc aag ttc	1347
Phe Tyr Lys Gln Pro Met Phe Tyr His Leu Gly His Phe Ser Lys Phe	
430 435 440 445	
att cct gag ggc tcc cag aga gtg ggg ctg gtt gcc agt cag aag aac	1395
Ile Pro Glu Gly Ser Gln Arg Val Gly Leu Val Ala Ser Gln Lys Asn	
450 455 460	
gac ctg gac gca gtg gca ctg atg cat ccc gat ggc tct gct gtt gtg	1443
Asp Leu Asp Ala Val Ala Leu Met His Pro Asp Gly Ser Ala Val Val	
465 470 475	
gtc gtg cta aac cgc tcc tct aag gat gtg cct ctt acc atc aag gat	1491
Val Val Leu Asn Arg Ser Ser Lys Asp Val Pro Leu Thr Ile Lys Asp	
480 485 490	
cct gct gtg ggc ttc ctg gag aca atc tca cct ggc tac tcc att cac	1539
Pro Ala Val Gly Phe Leu Glu Thr Ile Ser Pro Gly Tyr Ser Ile His	
495 500 505	
acc tac ctg tgg cat aga caa tga gacgcatgct ggtacccgaa ttcagcggcc	1593
Thr Tyr Leu Trp His Arg Gln	
510 515	

&lt;210&gt; 4

&lt;211&gt; 516

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 4

Met Ala Gly Ser Leu Thr Gly Leu Leu Leu Leu Gln Ala Val Ser Trp  
1 5 10 15

Ala Ser Gly Ala Arg Pro Cys Ile Pro Lys Ser Phe Gly Tyr Ser Ser  
20 25 30

Val Val Cys Val Cys Asn Ala Thr Tyr Cys Asp Ser Phe Asp Pro Pro  
35 40 45

Thr Phe Pro Ala Leu Gly Thr Phe Ser Arg Tyr Glu Ser Thr Arg Ser  
50 55 60

Gly Arg Arg Met Glu Leu Ser Met Gly Pro Ile Gln Ala Asn His Thr  
65 70 75 80

Gly Thr Gly Leu Leu Leu Thr Leu Gln Pro Glu Gln Lys Phe Gln Lys  
85 90 95

Val Lys Gly Phe Gly Gly Ala Met Thr Asp Ala Ala Ala Leu Asn Ile  
100 105 110

Leu Ala Leu Ser Pro Pro Ala Gln Asn Leu Leu Leu Lys Ser Tyr Phe  
115 120 125

Ser Glu Glu Gly Ile Gly Tyr Asn Ile Ile Arg Val Pro Met Ala Ser  
130 135 140

Cys Asp Phe Ser Ile Arg Thr Tyr Thr Tyr Ala Asp Thr Pro Asp Asp  
145 150 155 160

Phe Gln Leu His Asn Phe Ser Leu Pro Glu Glu Asp Thr Lys Leu Lys  
165 170 175

Ile Pro Leu Ile His Arg Ala Leu Gln Leu Ala Gln Arg Pro Val Ser  
180 185 190

Leu Leu Ala Ser Pro Trp Thr Ser Pro Thr Trp Leu Lys Thr Asn Gly  
195 200 205

Ala Val Asn Gly Lys Gly Ser Leu Lys Gly Gln Pro Gly Asp Ile Tyr  
210 215 220

His Gln Thr Trp Ala Arg Tyr Phe Val Lys Phe Leu Asp Ala Tyr Ala  
225 230 235 240

Glu His Lys Leu Gln Phe Trp Ala Val Thr Ala Glu Asn Glu Pro Ser  
245 250 255

Ala Gly Leu Leu Ser Gly Tyr Pro Phe Gln Cys Leu Gly Phe Thr Pro  
260 265 270

Glu His Gln Arg Asp Phe Ile Ala Arg Asp Leu Gly Pro Thr Leu Ala  
275 280 285

Asn Ser Thr His His Asn Val Arg Leu Leu Met Leu Asp Asp Gln Arg  
290 295 300

Leu Leu Leu Pro His Trp Ala Lys Val Val Leu Thr Asp Pro Glu Ala  
305 310 315 320

Ala Lys Tyr Val His Gly Ile Ala Val His Trp Tyr Leu Asp Phe Leu  
325 330 335

Ala Pro Ala Lys Ala Thr Leu Gly Glu Thr His Arg Leu Phe Pro Asn  
340 345 350

Thr Met Leu Phe Ala Ser Glu Ala Cys Val Gly Ser Lys Phe Trp Glu  
355 360 365

Gln Ser Val Arg Leu Gly Ser Trp Asp Arg Gly Met Gln Tyr Ser His  
370 375 380

Ser Ile Ile Thr Asn Leu Leu Tyr His Val Val Gly Trp Thr Asp Trp  
385 390 395 400

Asn Leu Ala Leu Asn Pro Glu Gly Gly Pro Asn Trp Val Arg Asn Phe  
405 410 415

Val Asp Ser Pro Ile Ile Val Asp Ile Thr Lys Asp Thr Phe Tyr Lys  
420 425 430

Gln Pro Met Phe Tyr His Leu Gly His Phe Ser Lys Phe Ile Pro Glu  
435 440 445

Gly Ser Gln Arg Val Gly Leu Val Ala Ser Gln Lys Asn Asp Leu Asp  
450 455 460

Ala Val Ala Leu Met His Pro Asp Gly Ser Ala Val Val Val Val Leu  
465 470 475 480

Asn Arg Ser Ser Lys Asp Val Pro Leu Thr Ile Lys Asp Pro Ala Val  
485 490 495

Gly Phe Leu Glu Thr Ile Ser Pro Gly Tyr Ser Ile His Thr Tyr Leu  
500 505 510

Trp His Arg Gln  
515

<210> 5

<211> 36

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)..(36)

<400> 5

ccctgagctc tgtgcacccc gatggctctg ctgttg

36

<210> 6

<211> 48

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)..(48)

<400> 6

cgtggtaccg gcatgcgtct cattgacggc gccacaggta ggtgtgaa

48



<210> 7

<211> 49

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)..(49)

<400> 7

cgaggtacca gcatgctct cattgtctat gccacaggta ggtgtgaat 49

<210> 8

<211> 41

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)..(41)

<400> 8

cgatgtctag aattcaaaat ggctggctcg ttaacaggat t 41

<210> 9

<211> 55

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)..(55)

<400> 9

gcttctactt caggcagtgt cgtgggcac cggagctaga ccttgcaccc ctaaa 55

<210> 10

<211> 44  
<212> DNA  
<213> Homo sapiens  
<220>  
<221> misc\_feature  
<222> (1)..(44)  
<400> 10  
agcttttagg gatgcaaggt ctagctccgg atgcccacga cact 44  
  
<210> 11  
<211> 54  
<212> DNA  
<213> Homo sapiens  
<220>  
<221> misc\_feature  
<222> (1)..(54)  
<400> 11  
gcctgaagta gaagcaatcc tgttaacgag ccagccattt tgaattctag acat 54  
  
<210> 12  
<211> 27  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SIGNAL  
<222> (1)..(27)  
<400> 12  
Met Ala Gly Ser Leu Thr Gly Leu Leu Leu Leu Gln Ala Val Ser Trp  
1 5 10 15  
Ala Ser Gly Ala Arg Pro Cys Ile Pro Lys Ser  
20 25

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 October 2001 (18.10.2001)

PCT

(10) International Publication Number  
**WO 01/77307 A3**

- (51) International Patent Classification?: C12N 9/24, 15/86, A61K 38/48
- (21) International Application Number: PCT/US01/11144
- (22) International Filing Date: 6 April 2001 (06.04.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/195,598 6 April 2000 (06.04.2000) US
- (71) Applicant (for all designated States except US): CYTOCLONAL PHARMACEUTICS, INC. [US/US]; 9000 Harry Hines Boulevard, Dallas, TX 75235 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): BERENT, Susan, L. [US/US]; 14343 Valley Hi Circle, Farmers Branch, TX 75234 (US).
- (74) Agents: HANSEN, Eugenia, S. et al.; Sidley & Austin, Suite 3400, 717 N. Harwood, Dallas, TX 75201 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report
- (88) Date of publication of the international search report:  
21 March 2002
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: EXPRESSION SYSTEM FOR EFFICIENTLY PRODUCING CLINICALLY EFFECTIVE LYSOSOMAL ENZYMES (GLUCOCEREBROSIDASE)

SEQ ID NO:1	—ATT	CAC	ACC	TAC	CTG	TGG	CGC	CGT	CAA	TGA
SEQ ID NO:2	—Ile	His	Thr	Tyr	Leu	Trp	Arg	Arg	Gln	
	508	509	510	511	512	513	514	515	516	
SEQ ID NO:3	—ATT	CAC	ACC	TAC	CTG	TGG	CAT	AGA	CAA	TGA
SEQ ID NO:4	—Ile	His	Thr	Tyr	Leu	Trp	His	Arg	Gln	
	508	509	510	511	512	513	514	515	516	

(57) Abstract: The invention as described herein relates to the efficient production of recombinant, clinically effective lysosomal enzymes using a transformed insect cell expression system. For example, to create the expression system of the invention, any insect cell can be transfected with a plasmid comprised of a gene encoding the human glucocerebrosidase gene and genetic elements that enhance its expression. The insect cell transfected with the plasmid encoding glucocerebrosidase secretes synthesized glucocerebrosidase into its growth media. The recombinantly produced clinically effective glucocerebrosidase produced by the insect cell expression system can be used to treat Gaucher's disease.

WO 01/77307 A3

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 01/11144

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 7 C12N9/24 C12N15/86 A61K38/48		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, BIOSIS, SEQUENCE SEARCH, WPI Data		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MARTIN B M ET AL: "GLYCOSYLATION AND PROCESSING OF HIGH LEVELS OF ACTIVE HUMAN GLUCOCEREBROSIDASE IN INVERTEBRATE CELLS USING A BACULOVIRUS EXPRESSION VECTOR" DNA (NEW YORK), vol. 7, no. 2, 1988, pages 99-106, XP001034134 ISSN: 0198-0238 cited in the application	1-5,9-53
Y	the whole document ---	2-4,6-8
X	US 5 879 680 A (ELIASON WILLIAM K ET AL) 9 March 1999 (1999-03-09) cited in the application	1-5,9-53
Y	the whole document ---	2-4,6-8
	--- -/--	
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family		
Date of the actual completion of the international search 3 December 2001		Date of mailing of the international search report 21/12/2001
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016		Authorized officer Petri, 8

# INTERNATIONAL SEARCH REPORT

International Application No

PCI/US 01/11144

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 549 892 A (HAYES MICHAEL ET AL) 27 August 1996 (1996-08-27) cited in the application	1-5,9-53
Y	the whole document	2-4,6-8
X	US 5 236 838 A (BARSOMIAN GARY ET AL) 17 August 1993 (1993-08-17) cited in the application	1-5,9-53
Y	the whole document	2-4,6-8
X	WO 90 07573 A (GENZYME CORP) 12 July 1990 (1990-07-12)	1-5,9-53
Y	the whole document	2-4,6-8
X	YANG JENG-DAR ET AL: "Rational scale-up of a baculovirus-insect cell batch process based on medium nutritional depth." BIOTECHNOLOGY AND BIOENGINEERING, vol. 52, no. 6, 1996, pages 696-706, XP001037783 ISSN: 0006-3592	1-5,9-53
Y	the whole document	2-4,6-8
X	US 5 759 809 A (IATROU KOSTAS) 2 June 1998 (1998-06-02) cited in the application	1,5-53
Y	the whole document	2-4
Y	column 13, line 37	
Y	LU MAOLONG ET AL: "A baculovirus (Bombyx mori nuclear polyhedrosis virus) repeat element functions as a powerful constitutive enhancer in transfected insect cells." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 49, 5 December 1997 (1997-12-05), pages 30724-30728, XP002184505 ISSN: 0021-9258 cited in the application the whole document page 30725, column 1, paragraph 2	6-8
A	ALTMANN F: "More than silk and honey - or, can insect cells serve in the production of therapeutic glycoproteins ?" GLYCOCONJUGATE JOURNAL, CHAPMAN & HALL, GB, vol. 14, 1997, pages 643-646, XP002140795 ISSN: 0282-0080 cited in the application page 645, column 1, line 40 - line 55	1-53
	--- -/--	

# INTERNATIONAL SEARCH REPORT

International Application No  
PCI/US 01/11144

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	<p>WO 01 49830 A (MAXYGEN APS) 12 July 2001 (2001-07-12) the whole document -----</p>	1-53

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/11144

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5879680	A	09-03-1999	US 6074864 A AU 2946289 A EP 0393143 A1 IL 88621 A WO 8905850 A1	13-06-2000 19-07-1989 24-10-1990 31-10-1995 29-06-1989
US 5549892	A	27-08-1996	US 5236838 A CA 2006709 A1 AT 138686 T DE 68926569 D1 DE 68926569 T2 EP 0401362 A1 ES 2093642 T3 JP 2893481 B2 WO 9007573 A1	17-08-1993 23-06-1990 15-06-1996 04-07-1996 26-09-1996 12-12-1990 01-01-1997 24-05-1999 12-07-1990
US 5236838	A	17-08-1993	US 5549892 A AT 138686 T CA 2006709 A1 DE 68926569 D1 DE 68926569 T2 EP 0401362 A1 ES 2093642 T3 JP 2893481 B2 WO 9007573 A1	27-08-1996 15-06-1996 23-06-1990 04-07-1996 26-09-1996 12-12-1990 01-01-1997 24-05-1999 12-07-1990
WO 9007573	A	12-07-1990	AT 138686 T CA 2006709 A1 DE 68926569 D1 DE 68926569 T2 EP 0401362 A1 ES 2093642 T3 JP 2893481 B2 US 5549892 A WO 9007573 A1 US 5236838 A	15-06-1996 23-06-1990 04-07-1996 26-09-1996 12-12-1990 01-01-1997 24-05-1999 27-08-1996 12-07-1990 17-08-1993
US 5759809	A	02-06-1998	US 6221632 B1 US 5989541 A AU 1377395 A CA 2179394 A1 WO 9517515 A1	24-04-2001 23-11-1999 10-07-1995 29-06-1995 29-06-1995
WO 0149830	A	12-07-2001	AU 2352201 A WO 0149830 A2	16-07-2001 12-07-2001